<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cardiovascular System - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  background: url("assets/background.jpg") center center / cover no-repeat fixed;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
}

body::before {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* Responsive utilities */
@media (max-width: 768px) {
  .glass-card {
    border-radius: 16px;
  }
  
  .glass {
    border-radius: 12px;
  }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">65</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="flex container mx-auto px-6 gap-8">
        <!-- Question Navigation Sidebar -->
        <div class="w-80 glass p-6 h-fit sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="flex-1 max-w-4xl">
            <div class="glass-card p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <!-- Explanation Video -->
                    <div id="solutionVideo" class="hidden">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

    <script>
        let questionsData = [
  {
    "id": 3588,
    "choices": [
      {
        "id": 14331,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a drug that can act by inhibiting angiotensin converting enzyme</span></span></span></p>"
      },
      {
        "id": 14332,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a drug used in combination with valsartan for congestive heart failure</span></span></span></p>"
      },
      {
        "id": 14333,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypokalemia is an adverse effect of sacubitril</span></span></span></p>"
      },
      {
        "id": 14334,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sacubitril is combined with ramipril for treatment of hypertension</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statement is True regarding Sacubitril?</span></span></span></p>",
    "unique_key": "Q1881193",
    "question_audio": null,
    "question_video": null,
    "map_id": 35980,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) It is a drug used in combination with valsartan for congestive heart failure</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sacubitril</strong> is a <strong>neprilysin inhibitor</strong> that <strong>increases </strong>the levels of <strong>natriuretic peptides </strong>by <strong>inhibiting their degradation</strong>. <strong>Neprilysin</strong> is responsible for <strong>degrading </strong>various peptides including <strong>natriuretic peptides, angiotensin II, bradykinin, and substance P.</strong> To counteract the potential excess of <strong>angiotensin II </strong>due to<strong> neprilysin inhibition, sacubitril </strong>is combined with an<strong> angiotensin receptor blocker (ARB),</strong> specifically <strong>valsartan.</strong> This combination, referred to as an <strong>angiotensin receptor-neprilysin inhibitor (ARNI),</strong> is approved for the treatment of<strong> heart failure. ARNI</strong> is specifically indicated to<strong> reduce the risk of cardiovascular death </strong>and <strong>hospitalization for heart</strong> failure in patients with<strong> chronic heart failure (NYHA Class II-IV) </strong>and<strong> reduced ejection fraction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect</strong> because <strong>sacubitril&nbsp;is not an angiotensin converting enzyme (ACE) inhibitor</strong>, which typically have names ending in -pril.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect </strong>as <strong>hypokalemia</strong>&nbsp;is <strong>not a side effect</strong> associated with <strong>sacubitril.</strong> It is <strong>more</strong> commonly associated with <strong>traditional</strong> <strong>diuretics </strong>rather than<strong> neprilysin inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>because <strong>sacubitril is combined with valsartan, not ramipril</strong>, and the combination is used for <strong>heart failure,</strong> not specifically for hypertension.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sacubitril is a neprilysin inhibitor </strong>used in combination<strong> with valsartan</strong> as an<strong> ARNI for the treatment of heart failure</strong> to <strong>reduce the risk</strong> of <strong>cardiovascular death and heart failure hospitalization</strong>, particularly in patients with<strong> reduced ejection fraction.</strong></span></span></span></p>",
    "correct_choice_id": 14332,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3856,
    "choices": [
      {
        "id": 15403,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine </span></span></span></p>"
      },
      {
        "id": 15404,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine</span></span></span></p>"
      },
      {
        "id": 15405,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivabradine </span></span></span></p>"
      },
      {
        "id": 15406,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fasudil</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs block late inward sodium ion channels?</span></span></span></p>",
    "unique_key": "Q7657781",
    "question_audio": null,
    "question_video": null,
    "map_id": 35989,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Ranolazine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine is known for its unique mechanism of action as a late inward sodium channel blocker. This property allows it to reduce the intracellular accumulation of sodium, which can reduce the calcium overload in cardiac cells through the sodium-calcium exchanger. By doing so, ranolazine helps to improve myocardial relaxation and decreases cardiac ischemia without significantly affecting the heart rate or blood pressure.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Trimetazidine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Trimetazidine acts as a partial fatty acid oxidation inhibitor, optimizing the energy metabolism of the heart during ischemia, but it does not block sodium channels.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ivabradine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ivabradine selectively inhibits the funny current (If) in the sinoatrial node, resulting in heart rate reduction, which can be beneficial in conditions like angina and heart failure, but it is not a sodium channel blocker.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Fasudil:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fasudil is a Rho-kinase inhibitor with vasodilatory effects and does not block sodium channels.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine is a late inward sodium channel blocker that can be used to treat chronic angina by improving myocardial relaxation and decreasing ischemia without major effects on heart rate or blood pressure.</span></span></span></p>",
    "correct_choice_id": 15403,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3594,
    "choices": [
      {
        "id": 14355,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Candesartan</span></span></span></p>"
      },
      {
        "id": 14356,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aliskiren</span></span></span></p>"
      },
      {
        "id": 14357,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinapril</span></span></span></p>"
      },
      {
        "id": 14358,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Benazepril</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is an oral renin inhibitor?</span></span></span></p>",
    "unique_key": "Q1095275",
    "question_audio": null,
    "question_video": null,
    "map_id": 35983,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Aliskiren&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aliskiren </strong>is an <strong>oral renin inhibitor</strong>, which acts by directly <strong>inhibiting the activity of renin.</strong> Renin is an enzyme that initiates the <strong>renin-angiotensin-aldosterone system (RAAS),</strong> leading to the production of<strong> angiotensin I,</strong> which is then <strong>converted to angiotensin II.</strong> <strong>Angiotensin II</strong> is a <strong>potent vasoconstrictor</strong> and <strong>stimulates aldosterone secretion,</strong> leading to<strong> increased blood pressure.</strong> By <strong>inhibiting</strong> <strong>renin</strong>, aliskiren<strong> reduces</strong> the formation of <strong>angiotensin I and II, </strong>thereby<strong> lowering blood pressure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Candesartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Candesartan is an <strong>angiotensin II receptor blocker (ARB)</strong>. It works by<strong> blocking the action of angiotensin II</strong> at its receptor, <strong>preventing angiotensin II </strong>from causing<strong> vasoconstriction and aldosterone</strong> release, which in turn <strong>lowers blood pressure.</strong> It <strong>does not inhibit renin </strong>directly.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Quinapril:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Quinapril is an <strong>angiotensin-converting enzyme (ACE) inhibitor</strong>. It inhibits the enzyme responsible for <strong>converting</strong> <strong>angiotensin I to angiotensin II, </strong>a<strong> potent vasoconstrictor.</strong> By<strong> reducing</strong> the levels of <strong>angiotensin II,</strong> it <strong>lowers blood pressure.</strong> Quinapril acts later in the<strong> RAAS pathway</strong> compared<strong> to aliskiren</strong> and <strong>does not directly inhibit renin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Benazepril:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Benazepril is also an <strong>ACE inhibitor,</strong> similar to<strong> quinapril. </strong>It<strong> lowers blood pressure</strong> by<strong> inhibiting </strong>the <strong>conversion of</strong> <strong>angiotensin I to angiotensin II,</strong> thereby <strong>reducing vasoconstriction</strong> and <strong>aldosterone-mediated volume expansion</strong>. Like <strong>quinapril,</strong> <strong>benazepril does not</strong> act by<strong> inhibiting renin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The objective is to understand the <strong>mechanisms of action </strong>of various drugs used in the<strong> management of hypertension,</strong> focusing on their roles within the <strong>renin-angiotensin-aldosterone system.</strong> Recognizing the unique action of <strong>aliskiren as a renin inhibitor,</strong> in <strong>contrast to ARBs and ACE inhibitors</strong> that<strong> act downstream,</strong> is essential for effective <strong>hypertension management. </strong></span></span></span></p>",
    "correct_choice_id": 14356,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3622,
    "choices": [
      {
        "id": 14467,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tolvaptan</span></span></span></p>"
      },
      {
        "id": 14468,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nesiritide</span></span></span></p>"
      },
      {
        "id": 14469,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrocortisone</span></span></span></p>"
      },
      {
        "id": 14470,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drug can be used for treatment of euvolemic hyponatremia in patient with advanced congestive heart failure?</span></span></span></p>",
    "unique_key": "Q9327063",
    "question_audio": null,
    "question_video": null,
    "map_id": 35981,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Tolvaptan&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tolvaptan</strong> is the appropriate drug for treating <strong>euvolemic hyponatremia </strong>in patients with <strong>advanced congestive heart failure (CHF)</strong>. <strong>Euvolemic hyponatremia</strong> is often caused by the<strong> syndrome of inappropriate secretion of antidiuretic hormone (SIADH),</strong> which is characterized by<strong> excessive retention of water</strong> with a <strong>dilutional drop in serum sodium.</strong> <strong>Tolvaptan acts</strong> as an orally active <strong>nonpeptide</strong> <strong>antagonist</strong> of the<strong> vasopressin V2 receptor</strong>, which mediates<strong> water reabsorption in the kidneys.</strong> By <strong>blocking </strong>this receptor, <strong>tolvaptan</strong> <strong>prevents water reabsorption, </strong>leading to an <strong>increase in water excretion, normalization of serum sodium levels</strong>, and <strong>alleviation of</strong> <strong>dyspnea </strong>related to<strong> CHF.</strong> While it is effective for <strong>short-term improvem</strong>ent, there are no noted long-term benefits.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Nesiritide:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>as nesiritide is a<strong> recombinant B-type natriuretic peptide</strong> used as a <strong>b</strong> decompensated heart failure, not specifically for<strong> euvolemic hyponatremia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hydrocortisone:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>because <strong>hydrocortisone</strong> is a<strong> corticosteroid </strong>and <strong>does not</strong> address the underlying mechanisms of <strong>euvolemic hyponatremia in CHF.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Metoprolol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as <strong>metoprolol is a beta-blocker</strong> used in the management of <strong>CHF and hypertension</strong>, but it is <strong>not used</strong> to directly treat<strong> euvolemic hyponatremia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with <strong>advanced congestive heart failure</strong> presenting with <strong>euvolemic hyponatremia, tolvaptan</strong> is used to <strong>correct water</strong> <strong>retention and hyponatremia associated with SIADH </strong>by <strong>antagonizing the vasopressin V2 receptors</strong> and <strong>increasing water excretion.</strong></span></span></span></p>",
    "correct_choice_id": 14467,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3660,
    "choices": [
      {
        "id": 14619,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a BNP analogue</span></span></span></p>"
      },
      {
        "id": 14620,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used in decompensated CHF</span></span></span></p>"
      },
      {
        "id": 14621,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be administered orally</span></span></span></p>"
      },
      {
        "id": 14622,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It causes loss of Na<sup>+</sup> in the urine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about nesiritide are true except? </span></span></span></p>",
    "unique_key": "Q3052889",
    "question_audio": null,
    "question_video": null,
    "map_id": 35985,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) It can be administered orally</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nesiritide</strong> is<strong> not </strong>available in an <strong>oral formulation </strong>because it is a <strong>peptide </strong>(<strong>Note</strong>: Drugs ending with <strong>&lsquo;tide&rsquo; are peptides)</strong>. <strong>Nesiritide</strong> is administered<strong> intravenously.</strong> It is a <strong>recombinant</strong> form of <strong>B-type natriuretic peptide (BNP),</strong> which is naturally produced by the <strong>ventricles of the heart.</strong> The <strong>intravenous administration </strong>is necessary because <strong>peptides typically undergo rapid degradation</strong> in the <strong>gastrointestinal tract</strong> and would be ineffective if administered orally.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. It is a BNP analogue:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true. Nesiritide</strong> is a <strong>synthetic</strong> version of <strong>BNP</strong> that is used in the management of <strong>acute decompensated heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. It can be used in decompensated CHF:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. <strong>Nesiritide</strong> is indicated for the <strong>treatment of acute</strong> <strong>decompensated congestive heart failure (CHF),</strong> where it works by causing<strong> vasodilation and natriuresis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. It causes loss of Na+ in the urine:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. Nesiritide promotes <strong>natriuresis,</strong> which is the<strong> excretion of sodium</strong> in the <strong>urine</strong>, contributing to its <strong>beneficial effects in heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>administration and effects of nesiritide </strong>in the treatment of<strong> acute decompensated heart</strong> <strong>failure</strong>. Nesiritide must be <strong>administered intravenously </strong>due to its <strong>peptide</strong> nature and the <strong>gastrointestinal degradation of oral peptides</strong></span></span></span></p>",
    "correct_choice_id": 14621,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3659,
    "choices": [
      {
        "id": 14615,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">They should be started with optimum doses</span></span></span></p>"
      },
      {
        "id": 14616,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">They should gradually increase over the weeks</span></span></span></p>"
      },
      {
        "id": 14617,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Special precautions should be taken in cases of NYHA class III and IV</span></span></span></p>"
      },
      {
        "id": 14618,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carvedilol and metoprolol are the preferred drugs</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are true about starting beta-blocker therapy in a patient with congestive heart failure except: </span></span></span></p>",
    "unique_key": "Q1070367",
    "question_audio": null,
    "question_video": null,
    "map_id": 35984,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) They should be started with optimum doses.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;In treating patients with <strong>congestive heart failure</strong>, particularly those with an <strong>ejection fraction &lt; 35% </strong>and <strong>NYHA Class II or III</strong> symptoms,<strong> beta-blockers</strong> are recommended alongside <strong>ACE inhibitors or angiotensin-receptor antagonists, and diuretics. </strong>However, <strong>beta-blockers </strong>should be initiated at <strong>very low doses</strong>, often<strong> less than one-tenth</strong> of the target dose. This is contrary to the statement in option a, as starting with <strong>&quot;optimum&quot; doses</strong> could be interpreted as <strong>beginning with the target or final dose</strong>, which is not the recommended approach. For <strong>NYHA Class IIIB and IV patients,</strong> clinicians should proceed with <strong>caution.</strong> <strong>Beta-blockers</strong> should <strong>not</strong> be initiated in recently <strong>decompensated heart failure </strong>until the patient has been<strong> stable for several days to weeks.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Gradually increasing the dose over weeks</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is <strong>correct</strong>, as this allows for the <strong>patient&rsquo;s tolerance to the drug</strong> to build and <strong>minimizes </strong>the <strong>risk of adverse effects. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Special precautions with NYHA class III and IV patients</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> are necessary due to their <strong>increased risk of fluid overload </strong>and <strong>worsening heart failure. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Carvedilol and metoprolol</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> are indeed the <strong>preferred beta-blockers</strong> for treating <strong>congestive heart failure</strong> due to their proven benefits in this patient population.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">When initiating <strong>beta-blocker </strong>therapy in <strong>congestive heart failure</strong>, it is essential to<strong> start with very low doses and titrate</strong> gradually to <strong>minimize risks</strong>, especially in patients with <strong>more advanced disease (NYHA class III and IV).</strong></span></span></span></p>",
    "correct_choice_id": 14615,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3662,
    "choices": [
      {
        "id": 14627,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It acts by causing prolonged opening of ATP dependent K<sup>+</sup> channels in beta cells</span></span></span></p>"
      },
      {
        "id": 14628,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can cause severe hypoglycemia</span></span></span></p>"
      },
      {
        "id": 14629,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used to treat patients with insulinoma</span></span></span></p>"
      },
      {
        "id": 14630,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used as an antihypertensive agent</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about diazoxide is false?</span></span></span></p>",
    "unique_key": "Q7270797",
    "question_audio": null,
    "question_video": null,
    "map_id": 35987,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) It can cause severe hypoglycemia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Diazoxide</strong> <strong>does not </strong>cause <strong>hypoglycemia</strong>; in fact, it has the opposite effect of causing <strong>hyperglycemia</strong>. The drug acts as a<strong> potassium</strong> <strong>channel opener,</strong> and when it<strong> opens ATP-dependent potassium channels</strong> in the pancreatic beta cells, this action results in <strong>decreased</strong> release of <strong>insulin</strong>. This would lead to <strong>increased blood glucose levels, </strong>which is why<strong> diazoxide can cause hyperglycemia. </strong>Its effect on the <strong>pancreatic beta cells</strong> is utilized therapeutically to treat <strong>insulinoma, </strong>a condition characterized by <strong>excessive insulin secretion,</strong> by <strong>reducing insulin release.</strong> In blood vessels, the<strong> opening of potassium channels causes vasodilation</strong>, which accounts for <strong>diazoxide&rsquo;s use</strong> as an<strong> antihypertensive agent.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true as diazoxide</strong> does cause <strong>prolonged opening of ATP-dependent K+ channels</strong> in pancreatic beta cells, leading to<strong> decreased insulin release. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>True</strong> because<strong> diazoxide </strong>is used in the treatment of<strong> insulinoma </strong>due to its <strong>ability to suppress insulin secretion</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>True</strong> since <strong>diazoxide</strong> has a<strong> vasodilatory effect </strong>due to its action on<strong> potassium channels in blood vessels, </strong>making it useful as an<strong> antihypertensive agent.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Diazoxide</strong> causes <strong>hyperglycemia</strong>, not hypoglycemia, by i<strong>nhibiting insulin release</strong> through the<strong> opening of K+ channels in pancreatic</strong> <strong>beta cells </strong>and is used in the treatment of <strong>insulinoma</strong> and as an<strong> antihypertensive agent </strong>due to its<strong> vasodilatory action.</strong></span></span></span></p>",
    "correct_choice_id": 14628,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3645,
    "choices": [
      {
        "id": 14559,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
      },
      {
        "id": 14560,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propanolol</span></span></span></p>"
      },
      {
        "id": 14561,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Encainide</span></span></span></p>"
      },
      {
        "id": 14562,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A new antiarrhythmic drug is found to be effective against both atrial and ventricular arrhythmias. Its effect on action potential is shown in the Figure. The effect of this new drug is most like:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/image-2-min.jpg\" style=\"height:168px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q6413034",
    "question_audio": null,
    "question_video": null,
    "map_id": 35992,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Quinidine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>graph</strong> provided<strong> shows an action potential curve </strong>with a<strong> prolonged plateau </strong>phase after<strong> drug therapy,</strong> which is characteristic of a drug that <strong>blocks potassium channels</strong>, thereby<strong> prolonging the duration of the action potential. </strong>The graph also depicts the <strong>decrease</strong> <strong>in slope of phase 0 </strong>which is characteristic of<strong> sodium channel blockers.</strong> This effect (<strong>sodium and potassium channel blockade</strong>) is seen with<strong> Class IA antiarrhythmic drugs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Among the options provided, <strong>Quinidine</strong> is <strong>known to have this effect on the action potential.</strong> Quinidine is a <strong>Class IA antiarrhythmic</strong> drug that <strong>not only blocks sodium channels (like Class I drugs) </strong>but also has the <strong>additional effect</strong> of <strong>blocking potassium channels,</strong> similar to<strong> Class III antiarrhythmics,</strong> which can lead to <strong>a prolonged action potential.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Lignocaine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Lignocaine (Lidocaine) is a <strong>Class IB antiarrhythmic drug</strong> that primarily works by <strong>shortening the action potential</strong> duration by <strong>blocking sodium channels</strong>, particularly in <strong>ischemic or depolarized cells</strong>. It<strong> does not</strong> prolong the <strong>action</strong> <strong>potential plateau.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Propranolol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Propranolol is a<strong> Class II antiarrhythmic</strong>, which is a <strong>beta-blocker </strong>that reduces<strong> sympathetic nervous system</strong> <strong>activity.</strong> It <strong>does not </strong>have a direct effect on the<strong> action potential duration or plateau phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Encainide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Encainide</strong>, which is<strong> no longer widely used,</strong> was a<strong> Class IC antiarrhythmic drug </strong>that significantly slows conduction by<strong> blocking sodium channels</strong> but <strong>does not </strong>typically prolong the<strong> action potential duration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to recognize the<strong> electrophysiologic effects of antiarrhythmic drugs</strong> on the cardiac action potential. Understanding how these drugs affect the <strong>action potential</strong> can provide insights into their <strong>therapeutic uses and potential</strong> <strong>arrhythmogenic risks. Quinidine&#39;s</strong> effect of <strong>prolonging the action potential duration</strong> is useful in the treatment of <strong>both atrial and</strong> <strong>ventricular arrhythmias,</strong> but it also carries the<strong> risk of proarrhythmia, </strong>underlining the need for<strong> careful patient selection </strong>and <strong>monitoring.</strong></span></span></span></p>",
    "correct_choice_id": 14562,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 3580,
    "choices": [
      {
        "id": 14299,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nesiritide</span></span></span></p>"
      },
      {
        "id": 14300,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sacubitril</span></span></span></p>"
      },
      {
        "id": 14301,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine</span></span></span></p>"
      },
      {
        "id": 14302,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs are used for treatment of congestive heart failure except:</span></span></span></p>",
    "unique_key": "Q3873872",
    "question_audio": null,
    "question_video": null,
    "map_id": 35991,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Trimetazidine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trimetazidine is an anti-anginal medication</strong> that <strong>improves myocardial glucose utilization </strong>by <strong>inhibiting fatty acid metabolism, </strong>leading to an <strong>energy-sparing effect in ischemic cells</strong>. However, it is <strong>not used </strong>in the treatment of <strong>congestive heart failure (CHF)</strong>; its <strong>primary use</strong> is in the management of <strong>angina pectoris.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Nesiritide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Nesiritide is a<strong> recombinant B-type natriuretic peptide</strong> that has <strong>vasodilatory effects </strong>and is used in the management of<strong> acute decompensated heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sacubitril:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> When<strong> combined with valsartan</strong> (a <strong>neprilysin inhibitor and an angiotensin II receptor blocker, </strong>respectively), sacubitril is used to<strong> reduce the risk of cardiovascular death </strong>and<strong> hospitalization for heart failure in patients</strong> with <strong>chronic heart</strong> <strong>failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Metoprolol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Metoprolol is a<strong> beta-blocker </strong>that is used in the management of<strong> CHF.</strong> It <strong>reduces myocardial oxygen demand</strong> and can <strong>improve survival in patients with heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-094413.png\" style=\"height:849px; width:1000px\" /></span></u></strong></span></span></p>",
    "correct_choice_id": 14301,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3735,
    "choices": [
      {
        "id": 14919,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
      },
      {
        "id": 14920,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Furosemide</span></span></span></p>"
      },
      {
        "id": 14921,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol succinate</span></span></span></p>"
      },
      {
        "id": 14922,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dobutamine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following medications has been shown to reduce mortality in heart failure with reduced ejection fraction?</span></span></span></p>",
    "unique_key": "Q9131620",
    "question_audio": null,
    "question_video": null,
    "map_id": 35990,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Metoprolol succinate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metoprolol succinate</strong>, a <strong>beta-1 selective adrenergic receptor blocker,</strong> has been shown in clinical trials to<strong> reduce mortality in patients</strong> with heart failure with reduced ejection fraction (HFrEF). It works by reducing the effects of <strong>catecholamines (stress</strong> <strong>hormones) on the heart, </strong>which in the setting of <strong>heart failure can be detrimental over time</strong>. By<strong> decreasing heart rate and myocardial</strong> <strong>contractility, </strong>it <strong>reduces myocardial oxygen demand </strong>and can<strong> improve the function of the heart.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Digoxin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While digoxin can<strong> improve symptoms and reduce hospitalizations by increasing the force of cardiac c</strong>ontractions and <strong>controlling heart rate</strong> in patients with <strong>heart failure,</strong> it<strong> has not been shown to reduce mortality </strong>in these patients.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Furosemide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Furosemide is a<strong> loop diuretic</strong> that is used to<strong> reduce symptoms of congestion in heart failure </strong>by promoting the<strong> excretion of sodium and water</strong>. However, it <strong>does not</strong> have a<strong> direct effect on reducing mortality in heart failure</strong> with <strong>reduced</strong> <strong>ejection fraction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Dobutamine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dobutamine is a<strong> beta-1 agonist</strong> used in <strong>acute heart failure to increase cardiac output</strong>. It is generally used for <strong>short-term support in hospitalized patients</strong> and is <strong>not </strong>shown to<strong> reduce long-term mortality in chronic heart failure</strong>; its long-term use can actually be<strong> harmful due to increased cardiac oxygen demand </strong>and potential for<strong> arrhythmia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the role of <strong>different classes of drugs </strong>in the treatment of <strong>heart failure</strong> with <strong>reduced ejection</strong> <strong>fraction,</strong> particularly those that <strong>have been demonstrated to reduce mortality.</strong> </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs reducing mortality in CHF include:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta blockers</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACE inhibitors</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ARBs</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aldosterone antagonists</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivabradine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydralazine + Isosorbide dinitrate</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 14921,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3629,
    "choices": [
      {
        "id": 14495,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary fibrosis</span></span></span></p>"
      },
      {
        "id": 14496,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corneal microdeposits</span></span></span></p>"
      },
      {
        "id": 14497,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Photosensitivity</span></span></span></p>"
      },
      {
        "id": 14498,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tachycardia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following are adverse effects of amiodarone except:</span></span></span></p>",
    "unique_key": "Q9450596",
    "question_audio": null,
    "question_video": null,
    "map_id": 35986,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Tachycardia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiodarone</strong> is a <strong>class III anti-arrhythmic</strong> drug known for its <strong>broad spectrum of action</strong>. <strong>Tachycardia is not an adverse effect</strong> of amiodarone; rather, the drug can <strong>cause bradycardia </strong>and may<strong> lead to a fall in blood pressure </strong>and <strong>myocardial depression</strong> when administered <strong>intravenously.</strong> This medication is <strong>notorious for a number of serious advrsee effects</strong>, particularly with <strong>prolonged use.</strong> The most severe include<strong> pulmonary fibrosis and alveolitis.</strong> <strong>Photosensitivity and skin pigmentation</strong> may occur in approximately 10% of patients taking amiodarone.<strong> Corneal microdeposits</strong> can result in <strong>vision disturbance</strong>s such as <strong>seeing halos around light</strong>s, commonly described as <strong>headlight dazzle,</strong> but this <strong>side effect is reversible upon discontinuation of the drug. </strong>Amiodarone may also cause<strong> peripheral neuropathy,</strong> which often presents as <strong>muscle weakness in the pelvic and shoulder regions</strong>. Additionally, it can <strong>interfere with thyroid function</strong> by <strong>preventing the peripheral conversion of thyroxine (T4) to triiodothyronine (T3), </strong>leading to <strong>hypothyroidism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pulmonary fibrosis:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a<strong> serious and well-recognized side effect of amiodarone,</strong> especially with <strong>long-term use.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Corneal microdeposits:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Common </strong>and typically <strong>reversible upon discontinuation of the drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Photosensitivity:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This<strong> adverse effect</strong> can occur in patients taking amiodarone<strong>, leading to increased risk of sunburn and skin</strong> <strong>pigmentation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiodarone</strong> is a <strong>class III anti-arrhythmic drug</strong> associated with <strong>several adverse effects </strong>including <strong>pulmonary fibrosis, corneal</strong> <strong>microdeposits, and photosensitivity,</strong> but not tachycardia; <strong>in fact, it more commonly causes bradycardia.</strong></span></span></span></p>",
    "correct_choice_id": 14498,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3837,
    "choices": [
      {
        "id": 15327,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procainamide</span></span></span></p>"
      },
      {
        "id": 15328,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flecanide</span></span></span></p>"
      },
      {
        "id": 15329,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
      },
      {
        "id": 15330,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sotalol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs are likely to produce the following ECG abnormality except: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/49.jpg\" style=\"height:175px; width:500px\" /></span></span></span></p>",
    "unique_key": "Q9547037",
    "question_audio": null,
    "question_video": null,
    "map_id": 35982,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Flecainide</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> ECG </strong>provided shows<strong> polymorphic ventricular tachycardia,</strong> also known as <strong>Torsades de pointes</strong>. This type of arrhythmia can arise from the b<strong>lockade of cardiac potassium (K) channels,</strong> which is a known <strong>side effect</strong> of certain <strong>classes of antiarrhythmics.</strong> Specifically, <strong>Class Ia antiarrhythmics like Quinidine and Procainamide,</strong> and<strong> Class III antiarrhythmics such as Amiodarone, Sotalol, Ibutilide, </strong>and <strong>Dofetilide, </strong>have been associated with the <strong>occurrence of Torsades de pointes</strong> due to their potential to <strong>prolong the QT interval </strong>on the <strong>ECG.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Procainamide:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Procainamide is a <strong>Class Ia antiarrhythmic</strong> that can<strong> block cardiac potassium channels</strong>, which may lead to <strong>QT prolongation </strong>and the potential development of<strong> Torsades de pointes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Quinidine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Quinidine, also a <strong>Class Ia antiarrhythmic,</strong> has similar effects on<strong> potassium channels</strong> and can cause <strong>QT</strong> <strong>prolongation and Torsades de pointes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Sotalol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Sotalol is a<strong> Class III antiarrhythmic</strong> that can cause<strong> QT prolongation</strong> and is known to be associated with the <strong>risk of</strong> <strong>Torsades de pointes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Flecainide, a Class Ic antiarrhythmic</strong>, primarily affects<strong> sodium channels</strong> and is<strong> less likely </strong>to cause<strong> QT prolongation,</strong> making it <strong>less</strong> likely to be associated with <strong>Torsades de pointes </strong>compared to the other drugs listed.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Flecainide</strong>, a <strong>Class Ic antiarrhythmic</strong> drug, is <strong>unlikely to cause QT prolongation </strong>and <strong>Torsades de pointes</strong> <strong>compared to Class Ia and III</strong> drugs, which can<strong> prolong the QT interval</strong> and are implicated in this<strong> arrhythmia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-123410.png\" style=\"height:488px; width:1000px\" /></span></span></span></p>",
    "correct_choice_id": 15328,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 3808,
    "choices": [
      {
        "id": 15211,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fasudil</span></span></span></p>"
      },
      {
        "id": 15212,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine</span></span></span></p>"
      },
      {
        "id": 15213,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine</span></span></span></p>"
      },
      {
        "id": 15214,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivabradine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a Rho kinase inhibitor?</span></span></span></p>",
    "unique_key": "Q4232288",
    "question_audio": null,
    "question_video": null,
    "map_id": 35978,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Fasudil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Fasudil </strong>is a <strong>Rho kinase inhibitor. </strong>Rho kinase is an<strong> enzyme</strong> that plays a significant role in<strong> smooth muscle contraction </strong>and other <strong>cellular processes</strong>. <strong>Inhibition</strong> of <strong>Rho kinase</strong> by <strong>fasudil </strong>leads to<strong> vasodilation</strong> making it useful for treatment of<strong> angina pectoris. </strong>It is also being investigated for the treatment of various <strong>cardiovascular disorders, including hypertension and pulmonary arterial</strong> <strong>hypertension, </strong>as well as for the<strong> prevention of cerebral vasospasm </strong>following<strong> subarachnoid hemorrhage.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Ranolazine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ranolazine is an<strong> anti-anginal medication. </strong>It works by<strong> inhibiting the late phase of the sodium </strong>current in the <strong>cardiac myocytes</strong>, thus <strong>reducing intracellular calcium overload </strong>and <strong>myocardial oxygen consumption.</strong> It <strong>does not</strong> act as a<strong> Rho kinase</strong> <strong>inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Trimetazidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Trimetazidine is an <strong>anti-ischemic (anti-anginal) metabolic agent</strong> that <strong>improves myocardial glucose</strong> utilization through<strong> inhibition of fatty acid metabolism.</strong> This action helps to<strong> maintain energy production in ischemic heart cells.</strong> <strong>Trimetazidine is not a Rho kinase inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ivabradine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ivabradine is a<strong> heart rate-reducing agent</strong> that works by<strong> inhibiting the If (funny) channel in the sinoatrial node</strong> <strong>of the heart</strong>, leading to a <strong>reduction in heart rate and myocardial oxygen demand.</strong> It is used for the treatment of <strong>chronic heart failure</strong> and <strong>stable angina pectoris</strong> in patients who<strong> cannot take beta-blockers</strong>. <strong>Ivabradine is not a Rho kinase inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the<strong> different mechanisms of action </strong>of various <strong>anti-anginal drugs. Fasudil as a Rho kinase</strong> <strong>inhibitor contrasts </strong>with<strong> ranolazine, trimetazidine, and ivabradine, </strong>which have different mechanisms. </span></span></span></p>",
    "correct_choice_id": 15211,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3745,
    "choices": [
      {
        "id": 14959,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Coronary vasodilation</span></span></span></p>"
      },
      {
        "id": 14960,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decrease heart rate</span></span></span></p>"
      },
      {
        "id": 14961,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased afterload</span></span></span></p>"
      },
      {
        "id": 14962,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreases preload</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The primary mechanism of action of nitrates in a patient of classical angina is:&nbsp;</span></span></span></p>",
    "unique_key": "Q4287837",
    "question_audio": null,
    "question_video": null,
    "map_id": 35979,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Decreases preload</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>primary action of nitrates</strong> in the treatment of <strong>classical angina</strong> is <strong>to decrease preload</strong>. <strong>Nitrates</strong> cause<strong> venous dilation,</strong> which reduces the <strong>volume of blood returning to the heart.</strong> This action <strong>decreases the heart&#39;s workload</strong> and its <strong>demand for oxygen,</strong> thereby <strong>alleviating the symptoms of angina</strong>. Please note, if nothing is mentioned in question, angina should be considered as classical angina.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Coronary Vasodilation</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Nitrates do </strong>cause some <strong>coronary vasodilation,</strong> but this is <strong>not their primary action</strong> in treating <strong>classical angina.</strong> <strong>Endothelium independent coronary vasodilation</strong> is the <strong>primary </strong>mechanism of <strong>nitrates </strong>in treatment of <strong>variant</strong> <strong>angina.</strong>&nbsp;In a typical vascular system, the<strong> endothelium</strong> plays a crucial role in <strong>regulating blood vessel tone and blood flow</strong>. It does this by releasing substances like<strong> nitric oxide (NO), </strong>which<strong> promote vasodilation.</strong>&nbsp;However, <strong>nitrates work independently of the endothelial</strong> <strong>cells.</strong> They are<strong> converted into nitric oxide (NO)</strong> <strong>within</strong> the <strong>smooth muscle cells.</strong> This<strong> NO</strong> then activates an enzyme called <strong>guanylate cyclase</strong>, which <strong>increases the levels of cyclic guanosine monophosphate (cGMP).</strong> The <strong>increase in cGMP </strong>leads to relaxation of the<strong> smooth muscle cells</strong>, resulting in <strong>vasodilatio</strong>n. This mechanism is particularly important in conditions like <strong>variant angina,</strong> where there are<strong> episodes of coronary artery spasm</strong>. <strong>Nitrate</strong>s can effectively <strong>relax the smooth muscle </strong>in the<strong> coronary arteries,</strong> <strong>reducing the spasm</strong> and thus <strong>alleviating the angina pain</strong>. This action is <strong>independent </strong>of the <strong>endothelium,</strong> which may <strong>not </strong>be <strong>functioning optimally </strong>in all individuals with <strong>coronary artery disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Decrease Heart Rate</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Nitrates <strong>do not</strong> have a significant effect on<strong> heart rate. </strong>Drugs that <strong>primarily decrease heart rate</strong>, such as <strong>beta-blockers</strong>, are used separately for this purpose in the management of angina.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Decrease Afterload</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While<strong> nitrates</strong> can have a <strong>minor effect on afterload </strong>due to <strong>systemic vasodilation</strong>, <strong>decreasing</strong> <strong>afterload</strong> is <strong>not </strong>their primary mechanism of action in<strong> treating angina</strong>. Medications like <strong>ACE inhibitors or angiotensin receptor</strong> <strong>blockers</strong> are<strong> more </strong>effective for this purpose.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>mechanism of action of nitrates</strong> in <strong>classical angina is decrease in preload.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>mechanism of action of nitrates</strong> i<strong>n variant angina</strong> is<strong> endothelium independent coronary vasodilation.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 14962,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3722,
    "choices": [
      {
        "id": 14867,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Guanylyl cyclase</span></span></span></p>"
      },
      {
        "id": 14868,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phosphokinase 1,2</span></span></span></p>"
      },
      {
        "id": 14869,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase A</span></span></span></p>"
      },
      {
        "id": 14870,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase B</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium nitroprusside acts by stimulation of?</span></span></span></p>",
    "unique_key": "Q5804759",
    "question_audio": null,
    "question_video": null,
    "map_id": 35988,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Guanylyl cyclase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sodium nitroprusside</strong> acts by directly <strong>stimulating guanylyl cyclase </strong>in<strong> vascular smooth muscle cells</strong>. This stimulation leads to an <strong>increase in intracellular cyclic guanosine monophosphate (cGMP),</strong> which then <strong>activates protein kinase G (PKG).</strong> The <strong>activation </strong>of <strong>PKG</strong> results in the <strong>dephosphorylation of myosin light chains</strong> in the smooth muscle, which <strong>induces relaxation and vasodilation. </strong>Due to this mechanism, <strong>sodium nitroprusside </strong>is effective in <strong>rapidly reducing blood pressure </strong>in <strong>hypertensive emergencies.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Phosphokinase 1,2:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> There is<strong> no </strong>enzyme specifically named <strong>phosphokinase 1,2. </strong>This option <strong>does not</strong> relate to the known mechanism of action of sodium nitroprusside.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Phospholipase A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Phospholipase A is an enzyme </strong>that <strong>hydrolyzes phospholipids</strong> to produce <strong>fatty acids</strong> and <strong>lysophospholipids</strong>. It is<strong> not </strong>directly involved in the <strong>mechanism of action of sodium nitroprusside.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Phospholipase B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Phospholipase B also <strong>acts on phospholipids </strong>but is<strong> not</strong> related to the<strong> vasodilatory action of sodium</strong> <strong>nitroprusside.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>pharmacodynamics of sodium nitroprusside</strong>, a <strong>potent vasodilator. </strong>By knowing that its mechanism involves th<strong>e stimulation of guanylyl cyclase </strong>and the subsequent<strong> increase in cGMP, </strong>healthcare professionals can better anticipate its effects and necessary precautions, such as <strong>monitoring for signs of cyanide toxicity</strong> due to its metabolism. Understanding the<strong> differences in mechanisms</strong> among various<strong> vasodilators </strong>is crucial for <strong>selecting the appropriate agent </strong>in clinical scenarios.</span></span></span></p>",
    "correct_choice_id": 14867,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3619,
    "choices": [
      {
        "id": 14455,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bradycardiac agent</span></span></span></p>"
      },
      {
        "id": 14456,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Rho kinase inhibition</span></span></span></p>"
      },
      {
        "id": 14457,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">K channel opener</span></span></span></p>"
      },
      {
        "id": 14458,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inhibiting mitochondrial LC3- KAT</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine is a drug approved for the treatment of angina pectoris. Its mechanism of action is assumed to be:</span></span></span></p>",
    "unique_key": "Q9218784",
    "question_audio": null,
    "question_video": null,
    "map_id": 36071,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Inhibiting mitochondrial LC3-KAT&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trimetazidine</strong> works through <strong>non-hemodynamic mechanisms,</strong> meaning it <strong>does not</strong> affect the determinants of <strong>myocardial oxygen</strong> consumption such as <strong>heart rate (HR) and blood pressure (BP) at rest or during exercise. </strong>Despite this, it<strong> reduces the frequency of</strong> <strong>angina attacks </strong>and <strong>increases exercise capacity. Trimetazidine&#39;s </strong>mechanism of action is <strong>postulated to enhance cellular tolerance </strong>to <strong>ischemia </strong>by<strong> inhibiting mitochondrial long-chain 3-ketoacyl-CoA thiolase (LC3-KAT),</strong> a key enzyme in <strong>fatty acid oxidation.</strong> This <strong>inhibition </strong>results in a shift from <strong>fatty acid metabolism to increased glucose metabolism in the myocardium. </strong>Since fatty acid <strong>oxidation requires more oxygen to produce the same amount of ATP as glucose</strong>, the <strong>shift to glucose metabolism</strong> leads to <strong>reduced</strong> <strong>oxygen demand</strong>. <strong>Trimetazidine</strong> is often referred to as a <strong>partial fatty acid oxidation (pFOX) inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect</strong> because<strong> ivabradine&nbsp;is the bradycardiac agent </strong>used <strong>for angina</strong>, which <strong>acts by blocking the funny current in the SA</strong> <strong>node</strong>, not trimetazidine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect</strong> as<strong> fasudil&nbsp;</strong>is the<strong> rho kinase inhibitor utilized for angina pectoris</strong>, not trimetazidine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect </strong>because <strong>nicorandil&nbsp;is the K channel opener </strong>(which also has<strong> nitric oxide releasing properties</strong>) that is<strong> used for</strong> <strong>angina pectoris, </strong>rather than trimetazidine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trimetazidine</strong> is an <strong>antianginal medication</strong> that <strong>reduces the frequency of angina attacks</strong> and <strong>increases exercise capacity </strong>through a mechanism that likely involves the <strong>inhibition of mitochondrial LC3-KAT, </strong>leading to a shift from <strong>fatty acid to glucose metabolism</strong> in the<strong> myocardium and resulting</strong> in a<strong> reduced oxygen demand.</strong></span></span></span></p>",
    "correct_choice_id": 14458,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3633,
    "choices": [
      {
        "id": 14511,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It binds to the intracellular face of Na<sup>+</sup> K<sup>+</sup> ATPase enzyme</span></span></span></p>"
      },
      {
        "id": 14512,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">There is rise in intracellular Na<sup>+</sup></span></span></span></p>"
      },
      {
        "id": 14513,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has positive ionotropic action</span></span></span></p>"
      },
      {
        "id": 14514,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inotropic action of digoxin is independent of cardiac innervation</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is not true about the mechanism of action of digitalis?</span></span></p>",
    "unique_key": "Q4426042",
    "question_audio": null,
    "question_video": null,
    "map_id": 36077,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) It binds to the intracellular face of Na+ K+ ATPase enzyme. </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Digitalis does not</strong> bind to the <strong>intracellular face of the Na+/K+ ATPase enzyme</strong>; instead, it <strong>binds</strong> to the <strong>extracellular face.</strong> The <strong>inhibition</strong> of this enzyme by <strong>digitalis causes a rise in intracellular sodium levels.</strong> As a consequence of <strong>increased intracellular sodium,</strong> the <strong>Na+/Ca2+ exchanger,</strong> which typically exports<strong> one calcium ion in exchange for three sodium ions,</strong> is <strong>inhibited</strong>. This leads to an <strong>increase in intracellular calcium levels</strong>. The elevated intracellular calcium enhances the <strong>contractility of the heart muscle</strong>, a mechanism known as<strong> positive inotropic action. </strong>Therefore, <strong>digitalis increases </strong>the <strong>force of cardiac contraction independently of</strong> <strong>cardiac innervation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. There is a rise in intracellular Na+:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is<strong> true;</strong> the<strong> inhibition of Na+/K+ ATPase</strong> by <strong>digitalis</strong> leads to <strong>increased</strong> <strong>intracellular sodium.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:Calibri,sans-serif\"><strong>Option</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>C. It has positive inotropic action:</strong> This is<strong> true;</strong> digitalis <strong>increases the force of cardiac muscle contraction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Inotropic action of digoxin is independent of cardiac innervation:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is also<strong> true;</strong> digitalis exerts its effects directly on the <strong>cardiac muscle cells, not </strong>through the<strong> nervous system.</strong> Though, it<strong> can decrease the AV conduction </strong>via<strong> vagus </strong>like action but this action is responsible for its<strong> use in atrial fibrillation</strong>,<strong> not as an inotropic drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Digitalis binds</strong> to the<strong> extracellular face of the Na+/K+ ATPase enzyme</strong>, leading to <strong>increased intracellular calcium,</strong> and in turn, <strong>positive inotropic action,</strong> which enhances<strong> cardiac contractility.</strong></span></span></span></p>",
    "correct_choice_id": 14511,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3617,
    "choices": [
      {
        "id": 14447,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
      },
      {
        "id": 14448,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dobutamine</span></span></span></p>"
      },
      {
        "id": 14449,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amrinone</span></span></span></p>"
      },
      {
        "id": 14450,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drug is used in CHF for relief of congestive symptoms and restoration of cardiac performance but does not possess inotropic action?</span></span></span></p>",
    "unique_key": "Q6890522",
    "question_audio": null,
    "question_video": null,
    "map_id": 36070,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Metoprolol&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metoprolol, a beta-blocker,</strong> is used in the management of<strong> congestive heart failure (CHF)</strong> for the relief of <strong>congestive symptoms</strong> and <strong>restoration of cardiac performance</strong>, but it <strong>does no</strong>t have<strong> inotropic action</strong>. Instead, <strong>metoprolol</strong> works by <strong>blocking beta-adrenergic</strong> <strong>receptors in the heart,</strong> leading to a<strong> reduction in heart rate</strong>, <strong>decrease in cardiac workload, </strong>and <strong>improvement in cardiac efficiency</strong> over time. This mechanism helps in<strong> managing CHF without</strong> directly increasing the<strong> force of heart contractions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Digoxin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Digoxin has a <strong>positive inotropic effect</strong>, <strong>increasing the force of cardiac contractions</strong>, and is used in<strong> CHF to improve</strong> <strong>symptoms and cardiac performance.</strong> It<strong> does not </strong>fit the criteria as it possesses <strong>inotropic action.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Dobutamine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dobutamine is a <strong>beta-1 adrenergic agonist </strong>with <strong>positive inotropic effects</strong>, used primarily in <strong>acute heart</strong> <strong>failure</strong> to <strong>increase cardiac output. </strong>It directly <strong>increases the force of heart contractions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Amrinone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amrinone is a <strong>phosphodiesterase inhibitor</strong> with <strong>positive inotropic and vasodilatory effects</strong>, used to <strong>improve</strong> <strong>cardiac output </strong>in heart failure patients. Like <strong>dobutamine and digoxin,</strong> it <strong>increases the force of cardiac contractions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the role of <strong>different classes of drugs</strong> in the management of <strong>CHF,</strong> particularly <strong>distinguishing</strong> those<strong> with and without inotropic action.</strong> <strong>Metoprolol&#39;s</strong> use in<strong> CHF illustrates</strong> the importance of managing <strong>heart rate and reducing</strong> <strong>myocardial oxygen demand</strong> as part of a strategy to <strong>improve cardiac performance</strong> <strong>without directly increasing the force of contraction</strong></span></span></span></p>",
    "correct_choice_id": 14450,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3795,
    "choices": [
      {
        "id": 15159,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nimodipine</span></span></span></p>"
      },
      {
        "id": 15160,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amlodipine</span></span></span></p>"
      },
      {
        "id": 15161,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diltiazem</span></span></span></p>"
      },
      {
        "id": 15162,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is used for reversal of cerebral vasospasm and infarct following subarachnoid hemorrhage? </span></span></span></p>",
    "unique_key": "Q9791712",
    "question_audio": null,
    "question_video": null,
    "map_id": 36078,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Nimodipine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nimodipine </strong>is a <strong>cerebroselective calcium channel blocker </strong>with a particular affinity for <strong>cerebral blood vessels.</strong> Its use is indicated for the management of <strong>cerebral vasospasm</strong>, which is a complication that can follow <strong>subarachnoid hemorrhage. </strong>This vasospasm typically <strong>manifests 4-5 days after the hemorrhage</strong>, potentially leading to <strong>cerebral ischemia, infarction, and neurological deficits</strong>. <strong>Nimodipine&#39;s </strong>action of <strong>blocking calcium influx into vascular smooth muscle</strong> leads to the <strong>relaxation of these vessels,</strong> thereby <strong>mitigating vasospasm</strong> and<strong> reducing the risk of infarction </strong>and its associated <strong>morbidity and mortality</strong>. This action makes it a valuable agent in<strong> improving neurological </strong>outcomes following a <strong>subarachnoid hemorrhage.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Amlodipine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While amlodipine is also a <strong>calcium channel blocker</strong>, it is not specifically indicated for<strong> cerebral vasospasm.</strong> It is more commonly used for<strong> hypertension and coronary artery disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Diltiazem:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Diltiazem is another <strong>calcium channel blocker</strong> with a <strong>broader cardiovascular effect profile </strong>and is <strong>not </strong>the drug of choice for<strong> cerebral vasospasm.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Verapamil:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Verapamil is a<strong> non-selective calcium channel blocker </strong>and is <strong>not</strong> specifically recommended for the treatment of <strong>cerebral vasospasm </strong>following <strong>subarachnoid hemorrhage.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nimodipine</strong> is used for the<strong> reversal of cerebral vasospasm and reducing mortality</strong> after <strong>subarachnoid hemorrhage,</strong> due to its s<strong>elective action on cerebral blood vessels.</strong></span></span></span></p>",
    "correct_choice_id": 15159,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette"
    ]
  },
  {
    "id": 3823,
    "choices": [
      {
        "id": 15271,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
      },
      {
        "id": 15272,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiloride</span></span></span></p>"
      },
      {
        "id": 15273,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cimetidine</span></span></span></p>"
      },
      {
        "id": 15274,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs can cause gynecomastia except:</span></span></span></p>",
    "unique_key": "Q1088630",
    "question_audio": null,
    "question_video": null,
    "map_id": 36076,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Amiloride</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiloride</strong> is a <strong>potassium-sparing diuretic</strong> that acts on the <strong>distal tubule of the nephron </strong>to <strong>inhibit sodium reabsorption</strong> and <strong>potassium excretion.</strong> It is<strong> not</strong> associated with the development <strong>of gynecomastia.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Digoxin:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Digoxin,</strong> a <strong>cardiac glycoside,</strong> has been associated with <strong>gynecomastia</strong> as a rare<strong> adverse effect, </strong>possibly due to its <strong>estrogen-like effects and alterations in hormone metabolism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Cimetidine:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cimetidine, a<strong> histamine H2 receptor antagonist</strong>, can cause <strong>gynecomastia </strong>by<strong> blocking androgen receptors </strong>and <strong>increasing prolactin secretion.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ketoconazole:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole, <strong>an antifungal agent, </strong>can <strong>inhibit testosterone synthesis </strong>by <strong>blocking cytochrome P450</strong> enzymes, leading to <strong>elevated estrogen levels </strong>and resulting in <strong>gynecomastia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to<strong> recognize medications associated with the development of gynecomastia a</strong>s an adverse effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IMPORTANT DRUGS CAUSING GYNAECOMASTIA:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DI: DI</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">goxin</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S: S</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">pironolactone</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C: C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">imetidine, <strong>K</strong>etoconazole</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">O: O</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">estrogens</span></span></span></p>",
    "correct_choice_id": 15272,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3772,
    "choices": [
      {
        "id": 15067,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
      },
      {
        "id": 15068,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiloride</span></span></span></p>"
      },
      {
        "id": 15069,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nicorandil</span></span></span></p>"
      },
      {
        "id": 15070,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methyldopa</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs act as K channel opener? </span></span></span></p>",
    "unique_key": "Q9655821",
    "question_audio": null,
    "question_video": null,
    "map_id": 36081,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Nicorandil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nicorandil </strong>is recognized for its distinctive role as a <strong>potassium (K) channel opener. </strong>By activating these channels, nicorandil causes the <strong>hyperpolarization of vascular smooth muscle cells,</strong> which leads to the<strong> relaxation and vasodilation of both arterial and venous blood vessels</strong>. This vasodilatory effect contributes to a<strong> reduction in the myocardial oxygen demand and</strong> <strong>enhances the blood flow to</strong> <strong>areas</strong> of the<strong> heart muscle that are ischemic. </strong>The<strong> efficacy of nicorandil </strong>in the treatment of<strong> angina pectoris is not solely </strong>due to its <strong>potassium channel opening </strong>properties; it also possesses <strong>nitrate-like properties</strong> that further amplify its <strong>anti-anginal effects </strong>by <strong>reducing preload and afterload on the heart.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Spironolactone:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Spironolactone is a<strong> potassium-sparing diuretic</strong> that works <strong>at the level of the distal convoluted tubule</strong> in the kidneys but <strong>does not act </strong>as a<strong> K channel opener</strong> in the cardiovascular system.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Amiloride:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amiloride is also a <strong>potassium-sparing diuretic</strong> that affects <strong>ion channels in the kidneys</strong>, but again, it <strong>does not</strong> <strong>open potassium channels </strong>in vascular smooth muscle.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Methyldopa:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Methyldopa is an <strong>antihypertensive medication</strong> that <strong>acts centrally as an alpha-2 agonist</strong> to<strong> lower blood</strong> <strong>pressure</strong>. It<strong> does not</strong> have<strong> K channel opening properties.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nicorandil</strong> acts as a<strong> K channel opener and has nitrate-like properties, </strong>making it effective in the <strong>treatment of angina pectoris</strong> due to its ability to <strong>reduce myocardial oxygen demand </strong>and<strong> increase blood flow to the ischemic heart muscle.</strong></span></span></span></p>",
    "correct_choice_id": 15069,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3749,
    "choices": [
      {
        "id": 14975,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduce the dose of ACE inhibitor</span></span></span></p>"
      },
      {
        "id": 14976,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Add anti- tussive for treatment of cough</span></span></span></p>"
      },
      {
        "id": 14977,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Change to Angiotensin receptor blocker (ARB)</span></span></span></p>"
      },
      {
        "id": 14978,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Order for a CT scan of chest</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old patient with essential hypertension on ACE inhibitors for 6 months developed chronic refractory dry cough. What would be the correct action to be taken?</span></span></span></p>",
    "unique_key": "Q4179287",
    "question_audio": null,
    "question_video": null,
    "map_id": 36073,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Change to Angiotensin receptor blocker (ARB)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Angiotensin-converting enzyme (ACE) inhibitors </strong>are known to induce a <strong>dry cough </strong>in approximately<strong> 5&ndash;10% of patients</strong>. The mechanism behind this adverse effect is thought to be related to the <strong>accumulation of bradykinin</strong>, which is <strong>not broken down</strong> as efficiently due to the<strong> inhibition of ACE.</strong> This <strong>side effect </strong>occurs more frequently in <strong>women</strong> than men and is <strong>not dose-related</strong>, as it can develop anytime between<strong> 1 week and 6 months after starting the therapy. </strong>In some cases, the<strong> persistent cough requires the cessation</strong> of<strong> ACE inhibitor therapy. </strong>It has been noted that <strong>once ACE inhibitors</strong> are stopped, the cough usually resolves within 4 days. Alternative medications like<strong> ARBs do not inhibit </strong>the <strong>degradation of bradykinin </strong>and are thus <strong>not </strong>associated with the <strong>side effect </strong>of a <strong>dry cough,</strong> making them a <strong>suitable alternative for hypertension management in patients </strong>who develop a <strong>cough with ACE inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Reduce the dose of ACE inhibitor:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Reducing the dose of the ACE inhibitor <strong>would not alleviate the cough </strong>since the adverse effect is not dose-related and the patient has already developed sensitivity to the drug.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Add anti-tussive for the treatment of cough:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> An anti-tussive <strong>would not</strong> address the underlying <strong>cause of the cough, </strong>which in this case is <strong>due to the ACE inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Order for a CT scan of the chest:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A CT scan would be an <strong>unnecessary investigation </strong>and an additional cost burden for the patient, given that the cause of the <strong>chronic cough is already known to be drug-related </strong>and<strong> not indicative of an underlying</strong> <strong>pulmonary pathology.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a patient who develops a <strong>chronic dry cough while on ACE inhibitors, </strong>changing to an <strong>Angiotensin receptor blocker (ARB)</strong> is the <strong>correct course of action,</strong> a<strong>s ARBs do not </strong>cause this<strong> side effect.</strong></span></span></span></p>",
    "correct_choice_id": 14977,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3626,
    "choices": [
      {
        "id": 14483,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyrotoxicosis</span></span></span></p>"
      },
      {
        "id": 14484,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Variant angina</span></span></span></p>"
      },
      {
        "id": 14485,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Migraine</span></span></span></p>"
      },
      {
        "id": 14486,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertension</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol can be used in all of the following conditions except.</span></span></span></p>",
    "unique_key": "Q7024934",
    "question_audio": null,
    "question_video": null,
    "map_id": 36075,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Variant angina&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Propranolol</strong> is <strong>contraindicated in variant angina (Prinzmetal&#39;s angina) </strong>because it is a<strong> non-selective beta-blocke</strong>r that can <strong>exacerbate</strong> <strong>symptoms. Variant angina </strong>is caused by <strong>coronary artery spasms,</strong> and<strong> beta-blockers </strong>like <strong>propranolol </strong>can<strong> increase the risk</strong> of these <strong>spasms</strong> by leaving <strong>unopposed alpha-mediated vasoconstriction</strong>, potentially worsening the condition.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Thyrotoxicosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Propranolol</strong> is used in <strong>thyrotoxicosis</strong> to provide <strong>symptomatic relief</strong> from<strong> hyperthyroid symptoms </strong>such as <strong>tachycardia, anxiety, and tremors</strong>. It can also <strong>inhibit peripheral conversion of T4 to T3.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Migraine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Propranolol</strong> is used as a<strong> prophylactic treatment for migraine</strong>. It helps <strong>reduce the frequency </strong>and <strong>severity of</strong> <strong>migraine attacks.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hypertension:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Propranolol </strong>can be used in the management of <strong>hypertension</strong>. It <strong>lowers blood pressure</strong> by <strong>reducing cardiac</strong> <strong>output</strong> and <strong>inhibiting</strong> <strong>renin</strong> release from the<strong> kidneys.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>therapeutic uses </strong>and <strong>contraindications of propranolol,</strong> a <strong>non-selective beta-blocke</strong>r. Recognizing that <strong>propranolol is contraindicated in variant angina </strong>due to its <strong>potential to worsen coronary artery spasms </strong>highlights the importance of considering the specific clinical context when selecting beta-blockers for treatment.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indications of &beta;-Blockers:</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/88.jpg\" style=\"height:439px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 14484,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 3780,
    "choices": [
      {
        "id": 15099,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></span></p>"
      },
      {
        "id": 15100,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenosine</span></span></span></p>"
      },
      {
        "id": 15101,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tenecteplase</span></span></span></p>"
      },
      {
        "id": 15102,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55 yr. old male presented to emergency with severe acute chest pain, radiating to left shoulder and back in the last 20 minutes. It was associated with sweating. ECG is shown in the figure. Which of the following drug should be given to the patient?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/42.jpg\" style=\"height:243px; width:500px\" /></span></span></span></p>",
    "unique_key": "Q4556105",
    "question_audio": null,
    "question_video": null,
    "map_id": 36072,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Tenecteplase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The description of the<strong> patient&#39;s symptoms</strong> along <strong>with the ECG (ST segment elevation in lead V1 to V5) </strong>makes the diagnosis of <strong>ST-segment elevation myocardial infarction (STEMI)</strong>. It would indicate the need for<strong> immediate reperfusion therapy. Tenecteplase </strong>is a <strong>fibrin-specific thrombolytic agent</strong> used in the management of <strong>STEMI </strong>to achieve <strong>reperfusion of the occluded coronary artery</strong>. It is given when <strong>primary percutaneous coronary intervention (PCI) </strong>is <strong>not </strong>available within the <strong>ideal time frame.</strong> <strong>Tenecteplase</strong> is <strong>administered </strong>to dissolve the<strong> thrombus</strong> that is<strong> blocking the coronary artery </strong>and causing the<strong> myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Amiodarone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amiodarone is an <strong>antiarrhythmic medication</strong> that is<strong> not </strong>indicated as an initial treatment for <strong>acute</strong> <strong>myocardial infarction</strong> unless there are accompanying<strong> life-threatening arrhythmias.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Adenosine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adenosine is typically<strong> used </strong>in the treatment of certain forms of <strong>supraventricular tachycardia </strong>and <strong>not</strong> in the setting<strong> </strong>of<strong> acute myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Verapamil:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Verapamil is a <strong>calcium channel blocker </strong>that is generally<strong> contraindicated</strong> in the setting of <strong>acute myocardial</strong> <strong>infarction,</strong> especially with evidence of<strong> STEMI,</strong> as it can further <strong>depress myocardial contractility</strong> and <strong>lead to hemodynamic</strong> <strong>deterioration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The objective is to recognize the <strong>appropriate use of thrombolytic therapy</strong> in the treatment of<strong> STEMI when PCI is not immediately</strong> <strong>available.</strong> <strong>Prompt</strong> initiation of<strong> thrombolytic therapy</strong> can significantly<strong> improve outcomes in STEMI </strong>by restoring <strong>coronary blood flow</strong> and <strong>minimizing myocardial damage.</strong></span></span></span></p>",
    "correct_choice_id": 15101,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 3844,
    "choices": [
      {
        "id": 15355,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rosuvastatin</span></span></span></p>"
      },
      {
        "id": 15356,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fenofibrate</span></span></span></p>"
      },
      {
        "id": 15357,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Evolocumab</span></span></span></p>"
      },
      {
        "id": 15358,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Niacin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old patient with a history of coronary artery disease and hyperlipidemia presents to the clinic for a routine follow-up. The patient is currently on atorvastatin for LDL cholesterol management but has recently had a lipid panel showing elevated Lipoprotein (a) levels. The patient is interested in exploring medication options that could specifically target the reduction of Lipoprotein (a) levels.&nbsp;Which of the following drugs is most likely to result in a reduction of Lipoprotein (a) levels?</span></span></span></p>",
    "unique_key": "Q1874354",
    "question_audio": null,
    "question_video": null,
    "map_id": 36074,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Niacin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Niacin, or Vitamin B3, </strong>has a distinctive role among <strong>lipid-lowering agents</strong> for its ability to significantly <strong>reduce Lipoprotein (a) levels.</strong> Although its precise mechanism of action in this context is<strong> not </strong>completely<strong> understood,</strong> <strong>niacin</strong> is believed to <strong>interfere with the</strong> <strong>synthesis and/or assembly of Lipoprotein (a) in the liver.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Rosuvastatin:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Statins</strong> like rosuvastatin are primarily known for<strong> their ability to lower LDL cholesterol </strong>but have a <strong>less</strong> pronounced effect on <strong>Lipoprotein (a).</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Fenofibrate:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fenofibrate is used for its <strong>potent triglyceride-lowering effects </strong>and <strong>does not</strong> have a significant impact on <strong>Lipoprotein (a) levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Evolocumab:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Evolocumab, a<strong> PCSK9 inhibitor, </strong>primarily<strong> lowers LDL cholesterol </strong>and has a relatively <strong>mild effect on reducing</strong> <strong>Lipoprotein (a) levels </strong>compared to <strong>niacin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Niacin is a lipid-lowering agent</strong> that can significantly <strong>reduce levels of Lipoprotein (a),</strong> distinguishing it from other<strong> lipid-modifying</strong> therapies that<strong> primarily focus on lowering LDL cholesterol or triglycerides.</strong></span></span></span></p>",
    "correct_choice_id": 15358,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3861,
    "choices": [
      {
        "id": 15423,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class Ia</span></span></span></p>"
      },
      {
        "id": 15424,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class Ib</span></span></span></p>"
      },
      {
        "id": 15425,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class Ic</span></span></span></p>"
      },
      {
        "id": 15426,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class II</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The anticonvulsant agent useful as an antiarrhythmic belongs to which class of antiarrhythmic drug?</span></span></span></p>",
    "unique_key": "Q1793602",
    "question_audio": null,
    "question_video": null,
    "map_id": 36079,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Class Ib</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenytoin, classified as a <strong>Class Ib antiarrhythmic drug</strong>, exerts its<strong> antiarrhythmic effects</strong> by<strong> blocking sodium channels. </strong>This action helps<strong> stabilize cell membranes and reduce abnormal electrical activity</strong> in the <strong>heart,</strong> making it useful in the management of certain <strong>types of arrhythmias.</strong> While phenytoin is <strong>primarily used as an anticonvulsant </strong>to <strong>control seizure</strong>s, its <strong>sodium channel-blocking</strong> properties also make it effective in<strong> treating ventricular arrhythmias.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Class Ia antiarrhythmics:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Drugs in this class, <strong>such as quinidine and procainamide</strong>, <strong>block sodium channels</strong> and prolong the <strong>action potential duration</strong>. While effective in <strong>treating arrhythmias, </strong>they are<strong> not</strong> commonly used as <strong>anticonvulsants.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Class Ic antiarrhythmics:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These drugs, <strong>including flecainide and propafenone,</strong> also<strong> block sodium channels </strong>but have <strong>minimal effects on action potential duration</strong>. They are primarily used for <strong>supraventricular arrhythmias</strong> and are <strong>not</strong> typically used as <strong>anticonvulsants.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Class II antiarrhythmics:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Class II drugs are <strong>beta-adrenergic blockers</strong>, such as<strong> propranolol and metoprolol,</strong> which <strong>reduce</strong> <strong>sympathetic stimulation of the heart</strong>. While they may have <strong>indirect effects on certain arrhythmias,</strong> they are<strong> not</strong> commonly used as <strong>anticonvulsants.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the <strong>classification of antiarrhythmic drugs</strong> and <strong>their mechanisms of action </strong>is crucial for <strong>selecting appropriate</strong> <strong>medications </strong>for the treatment of <strong>various arrhythmia</strong>s. Additionally, recognizing the <strong>dual utility of certain medications,</strong> like <strong>phenytoin, as both anticonvulsants and antiarrhythmics,</strong> enhances clinical decision-making in patients with overlapping conditions.</span></span></span></p>",
    "correct_choice_id": 15424,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3639,
    "choices": [
      {
        "id": 14535,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduced cardiac contractility</span></span></span></p>"
      },
      {
        "id": 14536,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased left ventricular end diastolic volume</span></span></span></p>"
      },
      {
        "id": 14537,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased diastolic perfusion pressure</span></span></span></p>"
      },
      {
        "id": 14538,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endothelium independent coronary vasodilatation</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient of Prinzmetal&rsquo;s angina is started on isosorbide mono nitrate. What is the mechanism of action of nitrates in this condition?</span></span></span></p>",
    "unique_key": "Q9854276",
    "question_audio": null,
    "question_video": null,
    "map_id": 36080,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Endothelium independent coronary vasodilatation</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Isosorbide mononitrate</strong>, when metabolized, <strong>releases nitric oxide (NO), </strong>which<strong> leads to the vasodilation of coronary arteries</strong>. This <strong>vasodilation is endothelium independent,</strong> meaning it<strong> does not</strong> rely on the <strong>endothelium cells of blood vessels to produce NO.</strong> <strong>Prinzmetal&#39;s (Variant/Vasospastic) angina</strong> is characterized by <strong>episodic angina </strong>due to <strong>coronary artery vasospasm,</strong> which<strong> temporarily</strong> <strong>reduces blood flow </strong>to the<strong> heart,</strong> producing <strong>ischemia and subsequent pain</strong>. The mechanism of action of nitrates, like <strong>isosorbide</strong> <strong>mononitrate, in Prinzmetal&rsquo;s angina</strong> involves the <strong>release of NO,</strong> which then <strong>binds to and activates guanylate cyclase</strong> in vascular smooth muscle cells. This activation <strong>leads to an increased level of intracellular cyclic guanosine monophosphate (cGMP)</strong>, which causes <strong>dephosphorylation of myosin light chain kinase (MLCK) </strong>and ultimately results in<strong> vascular smooth muscle relaxation </strong>and <strong>vasodilation of epicardial coronary arteries.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Reduced cardiac contractility:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> as <strong>nitrates do not</strong> primarily act by <strong>reducing the contractility of the heart.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Increased left ventricular end diastolic volume:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because <strong>nitrates do not </strong>typically <strong>increase left ventricular end-diastolic volume;</strong> they<strong> reduce preload and afterload</strong> through <strong>vasodilation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Decreased diastolic perfusion pressure:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>as <strong>nitrates do not reduce diastolic perfusion pressure;</strong> their action is aimed at <strong>reducing vasospasm and increasing perfusion.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In<strong> Prinzmetal&rsquo;s angina,</strong> nitrates like<strong> isosorbide mononitrate </strong>work by<strong> causing endothelium independent coronary vasodilation, </strong>acting directly on the<strong> vascular smooth muscle through NO donation, </strong>which <strong>leads to pain relief </strong>by <strong>reversing the coronary vasospasm.</strong></span></span></span></p>",
    "correct_choice_id": 14538,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3801,
    "choices": [
      {
        "id": 15183,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazides</span></span></span></p>"
      },
      {
        "id": 15184,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta adrenergic blocker</span></span></span></p>"
      },
      {
        "id": 15185,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACE inhibitor</span></span></span></p>"
      },
      {
        "id": 15186,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diazoxide</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with concomitant diabetes, anti-hypertensive agent of choice is? </span></span></span></p>",
    "unique_key": "Q9464287",
    "question_audio": null,
    "question_video": null,
    "map_id": 36025,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) ACE inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>ACE inhibitors</strong> are the preferred choice for<strong> hypertensive patients</strong> with <strong>diabetes </strong>because they have <strong>protective effects on the kidneys,</strong> which are often compromised in diabetic patients. They <strong>reduce blood pressure and decrease the progression of diabetic nephropathy</strong> by <strong>reducing intraglomerular pressure and proteinuria.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Thiazides:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Thiazide diuretics are effective <strong>antihypertensive</strong> agents but can<strong> affect carbohydrate metabolism </strong>and are <strong>not</strong> the<strong> first choice in patients with diabetes</strong>, as they can potentially <strong>worsen glycemic control.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Beta adrenergic blocker:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Beta-blockers <strong>can mask</strong> symptoms of <strong>hypoglycemia</strong> and may also affect <strong>lipid metabolism.</strong> Although they are<strong> effective for blood pressure control,</strong> they are<strong> not </strong>typically the<strong> first-line choice in diabetic patients</strong> unless there are<strong> other compelling indications such as heart failure or post-myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Diazoxide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Diazoxide is a<strong> vasodilator</strong> that can actually<strong> increase blood sugar levels </strong>by <strong>inhibiting insulin release </strong>from the <strong>pancreas</strong>. It is <strong>not </strong>used for routine treatment of <strong>hypertension </strong>and is certainly<strong> not the drug of choice in patients with diabetes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>appropriate choice of antihypertensive medication in patients with diabetes</strong>. <strong>ACE</strong> <strong>inhibitors offer renal protection </strong>and <strong>do not</strong> worsen <strong>glycemic control,</strong> making them a superior option for this patient population. Other properties of ACE inhibitors are also important for entrance exams.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Properties of ACE inhibitors</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>C</strong>ough</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>A</strong>ngioedema</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>P</strong>rodrugs (except captopril and Lisinopril)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>T</strong>aste disturbances</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">O&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>O</strong>rthostatic hypotension (when combined with diuretics)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>P</strong>regnancy (contra- indicated)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">R&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- bilateral&nbsp;<strong>R</strong>enal artery stenosis (contra-indicated)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">I&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>I</strong>ncreased K+ (contra-indicated)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">L&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>L</strong>ower the risk of diabetic nephropathy (Preferred drug in diabetic patients with hypertension)</span></span></span></p>",
    "correct_choice_id": 15185,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3598,
    "choices": [
      {
        "id": 14371,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
      },
      {
        "id": 14372,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></span></p>"
      },
      {
        "id": 14373,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
      },
      {
        "id": 14374,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenytoin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the drug of choice for digoxin induced ventricular tachyarrhythmias?</span></span></span></p>",
    "unique_key": "Q4310077",
    "question_audio": null,
    "question_video": null,
    "map_id": 36012,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Lignocaine&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Lignocaine</strong> is the <strong>drug of choice</strong> for treating <strong>ventricular tachyarrhythmias</strong> induced by <strong>digoxin toxicity.</strong> It works by stabilizing the <strong>cardiac membrane</strong> and is effective in <strong>treating digoxin-induced arrhythmias</strong> <strong>without </strong>further<strong> inhibiting the AV conduction, </strong>which is often already <strong>compromised in digoxin toxicity.</strong> Its use in this context is based on its ability to selectively target the<strong> arrhythmogenic</strong> <strong>effects without exacerbating the digoxin effect</strong> on the <strong>AV node.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Quinidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Quinidine is an <strong>antiarrhythmic</strong> that can<strong> increase serum digoxin levels </strong>and is<strong> contraindicated in digoxin-induced arrhythmias</strong> because it may <strong>exacerbate toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Amiodarone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While amiodarone is a<strong> versatile antiarrhythmic agent </strong>used in <strong>various types of arrhythmias</strong>, it can <strong>interact</strong> with <strong>digoxin and increase its levels</strong>, potentially <strong>worsening toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Phenytoin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Phenytoin is effective for <strong>ventricular arrhythmias, </strong>especially in the context of<strong> acute myocardial infarction,</strong> but it is<strong> not the first choice for digoxin-induced arrhythmias.</strong> It <strong>can be used </strong>if<strong> lignocaine is not available or contraindicated.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>appropriate management of digoxin-induced ventricular tachyarrhythmias</strong>. Recognizing <strong>lignocaine </strong>as the<strong> drug of choice </strong>in this scenario is <strong>critical for effectively addressing the cardiac toxicity </strong>associated with <strong>digoxin</strong> <strong>overdose</strong>, <strong>minimizing the risk </strong>of further <strong>cardiac complications.</strong></span></span></span></p>",
    "correct_choice_id": 14373,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3587,
    "choices": [
      {
        "id": 14327,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carvedilol</span></span></span></p>"
      },
      {
        "id": 14328,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
      },
      {
        "id": 14329,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nitroglycerine</span></span></span></p>"
      },
      {
        "id": 14330,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man presents with NYHA Class III breathlessness with a serum creatinine of 2.5 mg/dL and potassium level of 5.5 mEq/L. Which of the following drug is contraindicated?</span></span></span></p>",
    "unique_key": "Q2729165",
    "question_audio": null,
    "question_video": null,
    "map_id": 36009,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Spironolactone</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Spironolactone</strong> is contraindicated in this patient due to the<strong> presence of renal failure </strong>(as indicated by a <strong>serum creatinine of 2.5 mg/dL,</strong> where<strong> normal is less than 1 mg/dL</strong>) and<strong> higher normal levels of serum potassium (5.5 mEq/L</strong>, where normal range is <strong>3.5&ndash;5.5</strong> <strong>mEq/L)</strong>. Spironolactone is a<strong> potassium-sparing diuretic</strong> and <strong>aldosterone antagonist </strong>which is beneficial in <strong>chronic heart failure</strong> <strong>(CHF) patients,</strong> particularly those with<strong> hypokalemia,</strong> as it prevents<strong> cardiac remodeling.</strong> However, it is <strong>contraindicated </strong>in the presence of <strong>deranged renal function</strong> because it could lead to the development of <strong>severe hyperkalemia</strong>. This risk remains even when the <strong>serum potassium level is high normal.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Carvedilol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>as beta blockers like <strong>carvedilol </strong>are <strong>indicated in CHF and can reduce mortality.</strong> They should be <strong>started</strong> <strong>at a very low dose</strong> and gradually titrated<strong> to</strong> the <strong>target dose.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Nitroglycerine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> because<strong> nitroglycerine is a vasodilator</strong> that can help<strong> reduce the workload of the heart</strong> and provide<strong> symptomatic relief in CHF.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Digoxin:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as digoxin is an <strong>oral inotropic agent </strong>that can be used in <strong>chronic CHF</strong> to <strong>improve </strong>symptoms and possibly <strong>exercise capacity. </strong>Although it is excreted by kidneys but it can be used in renal failure after dose adjustment.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with <strong>CHF and compromised renal function</strong> or <strong>elevated serum potassium levels</strong>,<strong> potassium-sparing diuretics</strong> like <strong>spironolactone </strong>should b<strong>e avoided </strong>due to the<strong> increased risk of severe hyperkalemia.</strong></span></span></span></p>",
    "correct_choice_id": 14328,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3817,
    "choices": [
      {
        "id": 15247,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flecainide</span></span></span></p>"
      },
      {
        "id": 15248,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tocainide</span></span></span></p>"
      },
      {
        "id": 15249,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procainamide</span></span></span></p>"
      },
      {
        "id": 15250,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ibutilide</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the antiarrhythmic agent with the following mechanism of action? </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/14/whatsapp-image-2024-02-14-at-35057-pm.jpeg\" style=\"height:225px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q5340411",
    "question_audio": null,
    "question_video": null,
    "map_id": 36026,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Flecainide</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The graph shows an<strong> action potential of a cardiac myocyte</strong> with a marked <strong>block of sodium channels </strong>and <strong>no change in the</strong> <strong>repolarization phase</strong>. This description is consistent with the action of<strong> Class IC antiarrhythmic drugs,</strong> which significantly<strong> slow the</strong> <strong>conduction of the cardiac impuls</strong>e through the<strong> myocardium by blocking sodium channels without </strong>affecting the <strong>duration of the</strong> <strong>action potential. Flecainide</strong> is a<strong> Class IC antiarrhythmic drug</strong> that exhibits a marked<strong> blockade of sodium channels,</strong> which <strong>slows</strong> <strong>conduction throughout the heart</strong>. It <strong>does not</strong> significantly prolong the<strong> action potential </strong>or <strong>affect repolarization</strong>, which is consistent with the graph shown.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Tocainide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tocainide is a <strong>Class IB antiarrhythmic agent.</strong> Class IB drugs tend to <strong>shorten the action potential </strong>duration rather than having <strong>no change in repolarization.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Procainamide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procainamide is <strong>a Class IA antiarrhythmic agent</strong> that <strong>not only blocks sodium channels</strong> but also has a <strong>moderate effect on repolarization,</strong> leading to a<strong> slight prolongation of the action potential,</strong> which is not depicted in the graph.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ibutilide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ibutilide is a<strong> Class III antiarrhythmic drug</strong> that acts by <strong>prolonging repolarization</strong> through<strong> potassium channel</strong> <strong>blockade, </strong>which would <strong>lengthen the action potential, </strong>contrary to what is shown in the graph.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to recognize the <strong>electrophysiologic profiles</strong> of <strong>different classes of antiarrhythmic drugs.</strong> <strong>Class IC</strong> <strong>antiarrhythmics like flecainide </strong>are characterized by their <strong>potent sodium channel-blocking effects</strong> with <strong>minimal impact </strong>on the <strong>duration of the action potential.</strong> Understanding these properties is important for the <strong>appropriate selection and use of antiarrhythmic drugs in clinical practice.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/image-3-1.jpg\" style=\"height:978px; width:600px\" /></span></span></span></p>",
    "correct_choice_id": 15247,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 3665,
    "choices": [
      {
        "id": 14639,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pregnancy induced hypertension</span></span></span></p>"
      },
      {
        "id": 14640,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renovascular hypertension</span></span></span></p>"
      },
      {
        "id": 14641,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">First line agent in hypertension</span></span></span></p>"
      },
      {
        "id": 14642,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Refractory hypertension</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha methyldopa is primarily used for treatment of: </span></span></span></p>",
    "unique_key": "Q7718915",
    "question_audio": null,
    "question_video": null,
    "map_id": 36022,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Pregnancy induced hypertension</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Alpha methyldopa</strong> is primarily utilized for managing <strong>hypertension during pregnancy.</strong> It is considered <strong>safe for use </strong>in pregnant women when<strong> blood pressure control </strong>is necessary. As a <strong>prodrug, methyldopa </strong>is metabolized to its <strong>active form</strong>, which <strong>acts as an agonist at</strong> <strong>alpha-2 adrenergic receptors in the brain.</strong> This action leads to a<strong> decrease in central sympathetic outflow, t</strong>hereby <strong>lowering blood</strong> <strong>pressure.</strong> Its use in<strong> pregnancy-induced hypertension </strong>is due to its<strong> efficacy and safety profile for both the mother and the fetus.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Renovascular hypertension:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> as <strong>alpha methyldopa </strong>is <strong>not </strong>the first choice of treatment for <strong>renovascular</strong> <strong>hypertension. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. First line agent in hypertension:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>because <strong>alpha methyldopa</strong> is<strong> not </strong>commonly used as a <strong>first-line treatment for</strong> <strong>essential hypertension. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Refractory hypertension:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> as <strong>alpha methyldopa</strong> is<strong> not</strong> typically reserved for <strong>refractory hypertension </strong>but could be used if other options are unsuitable.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Alpha methyldopa </strong>is mainly used for the treatment of <strong>hypertension in pregnancy</strong> due to its <strong>efficacy and safety profile, </strong>acting through<strong> central mechanisms by stimulating alpha-2 adrenergic receptors.</strong></span></span></span></p>",
    "correct_choice_id": 14639,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3669,
    "choices": [
      {
        "id": 14655,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It causes direct relaxation of the blood vessels</span></span></span></p>"
      },
      {
        "id": 14656,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It causes dilatation of both arteries and veins</span></span></span></p>"
      },
      {
        "id": 14657,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Postural hypotension is not a common problem</span></span></span></p>"
      },
      {
        "id": 14658,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It increases plasma renin activity</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about hydralazine is not true?</span></span></span></p>",
    "unique_key": "Q8437876",
    "question_audio": null,
    "question_video": null,
    "map_id": 36023,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) It causes dilatation of both arteries and veins</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hydralazine </strong>primarily causes<strong> arteriolar dilation </strong>rather than venous dilation, which is why option b is not true. It works by a <strong>direct</strong> <strong>action on vascular smooth muscle, </strong>leading to <strong>vasodilation</strong>. This is believed to involve the release of nitric oxide (NO) and the<strong> opening</strong> of<strong> potassium channels</strong>. The<strong> dilatory effect of hydralazine</strong> is more pronounced in <strong>arteries</strong>, which is why it<strong> does not c</strong>ommonly cause <strong>postural hypotension</strong>&mdash;a condition <strong>usually</strong> associated with<strong> venous dilation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Correct</strong> as<strong> hydrala</strong>zine does cause <strong>direct relaxation of blood vessels, </strong>particularly <strong>arterioles. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Correct </strong>because <strong>postural hypotension</strong> is <strong>not a</strong> common problem with <strong>hydralazine, </strong>as it<strong> does not</strong> significantly <strong>dilate veins. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Correct as vasodilators like hydralazine</strong> can cause an<strong> increase in plasma renin activity </strong>due to<strong> compensatory mechanisms</strong> following a <strong>decrease in blood pressure</strong>, such as <strong>increased sympathetic activity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hydralazine</strong> is an <strong>antihypertensive agent </strong>that predominantly causes <strong>arteriolar dilation,</strong> resulting in <strong>decreased blood pressure</strong> <strong>without </strong>significantly affecting <strong>veins or causing postural hypotension.</strong></span></span></span></p>",
    "correct_choice_id": 14656,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3696,
    "choices": [
      {
        "id": 14763,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It acts by causing a reduction in central sympathetic outflow </span></span></span></p>"
      },
      {
        "id": 14764,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It increases LDL-cholesterol on prolonged use </span></span></span></p>"
      },
      {
        "id": 14765,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sedation and xerostomia are common side effects of clonidine</span></span></span></p>"
      },
      {
        "id": 14766,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be combined with vasodilators</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements are true about the use of clonidine in the treatment of hypertension except:</span></span></span></p>",
    "unique_key": "Q1228608",
    "question_audio": null,
    "question_video": null,
    "map_id": 36028,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) It increases LDL-cholesterol on prolonged use</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Clonidine</strong> <strong>does not</strong> <strong>increase LDL-cholesterol</strong> with prolonged use; in fact, it is known to <strong>decrease LDL and increase HDL-cholesterol.</strong> Clonidine is an <strong>alpha-2 adrenergic agonist</strong> that acts <strong>centrally to reduce sympathetic outflow, </strong>which in turn <strong>lowers blood pressure</strong>. It is <strong>effective</strong> when used <strong>alone or in combination</strong> with other <strong>antihypertensive agents, </strong>including <strong>vasodilators. </strong>Combining <strong>clonidine</strong> with <strong>vasodilators </strong>can be particularly beneficial because it can prevent the<strong> reflex increase in renin release</strong> that <strong>vasodilators often cause.</strong> <strong>Sedation and dry mouth (xerostomia)</strong> are indeed common <strong>side effects </strong>associated with <strong>clonidine use.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Correct </strong>as <strong>clonidine decreases central sympathetic outflow</strong> due to its <strong>alpha-2 agonist action. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Correct</strong> since<strong> sedation and xerostomia are well-documented side effects of clonidine. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Correct</strong> because<strong> clonidine can be combined with vasodilators</strong> to treat <strong>hypertension effectively.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Clonidine, an alpha-2 agonist</strong>, is used in the treatment of<strong> hypertension,</strong> primarily by <strong>reducing central sympathetic outflow</strong> and <strong>not</strong> by <strong>increasing LDL-cholesterol;</strong> it actually tends to have a<strong> beneficial effect on cholesterol profiles.</strong></span></span></span></p>",
    "correct_choice_id": 14764,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3701,
    "choices": [
      {
        "id": 14783,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Atrial fibrillation</span></p>"
      },
      {
        "id": 14784,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Bradycardia with AV block</span></p>"
      },
      {
        "id": 14785,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Torsades de pointes</span></p>"
      },
      {
        "id": 14786,
        "text": "<p><span style=\"font-size:12pt;\">Tachycardia</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A patient was taking verapamil for PSVT prophylaxis. He was given propranolol for treatment of essential tremors. This combination can result in:</span></p>",
    "unique_key": "Q2136101",
    "question_audio": null,
    "question_video": null,
    "map_id": 36029,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. B) Bradycardia with AV block</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Both propranolol</strong> and <strong>verapamil </strong>have <strong>negative chronotropic effects,</strong> meaning they <strong>decrease heart rate</strong>. <strong>Propranolol</strong> does this by <strong>blocking beta-1 adrenergic receptors,</strong> primarily affecting the <strong>sinoatrial (SA) node</strong>, while <strong>verapamil blocks L-type calcium channels,</strong> which are critical for <strong>impulse conduction</strong> through the <strong>atrioventricular (AV) node.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Adding <strong>verapamil </strong>to a patient already on <strong>propranolol increases the risk of additive effects</strong> on<strong> heart rate and conduction. </strong>This can lead to<strong> bradycardia, </strong>which is an <strong>abnormally slow heart rate,</strong> and in more severe cases, can <strong>progress to AV block.</strong> AV block occurs when the <strong>electrical conduction </strong>between the<strong> atria and ventricles</strong> is <strong>impaired,</strong> potentially leading to <strong>serious heart rhythm</strong> <strong>abnormalities </strong>and symptoms such as <strong>dizziness and fatigue.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Atrial fibrillation</strong> is <strong>not</strong> the most likely <strong>outcome </strong>of adding <strong>verapamil to propranolol </strong>therapy, although <strong>verapamil is</strong> sometimes used<strong> to control ventricular rate </strong>in patients with <strong>atrial fibrillation.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. Torsades\u2019</strong> de pointes is a<strong> specific type of ventricular tachycardia</strong> often associated with a<strong> prolonged QT interval</strong>, which is <strong>not a typical side effect </strong>of either <strong>propranolol or verapamil.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Tachycardia</strong>, or<strong> increased heart rate</strong>, would be <strong>unlikely as both drug</strong>s work to<strong> slow the heart rate.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational Objectives:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Therefore, the most appropriate answer in the context of this clinical scenario is<strong>&nbsp;B. Bradycardia</strong> with <strong>AV block, </strong>considering the <strong>pharmacological actions of both propranolol and verapamil</strong> and the <strong>symptoms </strong>reported by the patient.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ref: KDT 8th/160</strong></span></p>",
    "correct_choice_id": 14784,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3726,
    "choices": [
      {
        "id": 14883,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Aliskiren</span></p>"
      },
      {
        "id": 14884,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Digoxin</span></p>"
      },
      {
        "id": 14885,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Ivabradine</span></p>"
      },
      {
        "id": 14886,
        "text": "<p><span style=\"font-size:12pt;\">Valsartan</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A 72-year-old woman with a history of ischemic cardiomyopathy and left ventricular ejection fraction of 35%. She is NYHA class II in terms of symptoms. She is on lisinopril, carvedilol, and spironolactone. Her blood pressure is 102/82 mmHg, and heart rate is 80 bpm. Which of the following additional medications will further reduce her risk of hospitalization due to heart failure?</span></p>",
    "unique_key": "Q7749385",
    "question_audio": null,
    "question_video": null,
    "map_id": 36013,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. C) Ivabradine</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ivabradine </strong>is an appropriate choice for this patient because it <strong>reduces heart rate without </strong>causing <strong>myocardial depression</strong>. It works by selectively<strong> inhibiting the If (funny) channels in the sinoatrial node,</strong> which are responsible for <strong>regulating heart rate. </strong>In patients with <strong>heart failure</strong> who are in <strong>sinus rhythm</strong> with a<strong> heart rate of 70 bpm or higher,</strong> despite optimal treatment with <strong>beta-blockers </strong>or those who are <strong>intolerant to beta-blockers, ivabradine has been</strong> shown to <strong>reduce hospitalization </strong>due to<strong> heart failure</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Aliskiren:&nbsp;</strong>Aliskiren is a <strong>direct renin inhibitor</strong> and is used to treat<strong> hypertension. </strong>While it can <strong>reduce blood pressure</strong> and has been studied in<strong> heart failure</strong>, it is<strong> not </strong>specifically indicated to <strong>reduce mortality in heart failure patients</strong>, particularly when already on optimal therapy with an <strong>ACE inhibitor, beta-blocker, and aldosterone antagonist.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B. Digoxin:</strong> Digoxin may help <strong>improve </strong>symptoms and<strong> reduce hospitalizations</strong> by <strong>increasing contractility and controlling heart rate, </strong>but it<strong> has not </strong>been shown to<strong> reduce mortality in heart failure patients.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Valsartan:&nbsp;</strong>The patient is already on <strong>lisinopril, an ACE inhibitor, </strong>which provides the <strong>mortality benefit of inhibiting the renin-angiotensin-aldosterone system (RAAS). </strong>Adding another RAAS inhibitor like <strong>valsartan, an ARB, without removing the ACE inhibitor </strong>is <strong>not </strong>typically recommended due to <strong>increased risk of adverse effects without additional mortality benefit.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ivabradine </strong>can be used in <strong>certain heart failure </strong>patients with a <strong>high heart rate </strong>despite optimal standard therapy to further <strong>reduce the risk of heart failure-related morbidity. </strong>It is important to <strong>recognize the therapeutic benefits</strong> and<strong> limitations of</strong> <strong>additional heart failure</strong> treatments in the context of a patient's overall medical regimen and clinical status.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Ref</u>: CMDT 2022 Pg 410</strong></span></p>",
    "correct_choice_id": 14885,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3768,
    "choices": [
      {
        "id": 15051,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chlorthalidone</span></span></span></p>"
      },
      {
        "id": 15052,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triamterene</span></span></span></p>"
      },
      {
        "id": 15053,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
      },
      {
        "id": 15054,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Furosemide</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preferred drug for the treatment of uncomplicated grade 2 hypertension in a 48-year-old man is? </span></span></span></p>",
    "unique_key": "Q1827121",
    "question_audio": null,
    "question_video": null,
    "map_id": 36019,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Chlorthalidone</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chlorthalidone</strong> is a <strong>thiazide-like diuretic</strong> that is often preferred for the initial treatment of <strong>hypertension</strong>, including <strong>grade 2</strong> <strong>hypertension, </strong>which is defined as a<strong> systolic blood pressure of 140-159 mmHg or a diastolic blood pressure of 90-99 mmHg</strong>. <strong>Chlorthalidone </strong>helps to <strong>lower blood pressure by promoting the excretion of sodium and water</strong>, which<strong> reduces the volume of fluid in the blood vessels and lowers blood pressure</strong>. Its <strong>long half-life </strong>and evidence for <strong>reducing cardiovascular outcomes </strong>make it a suitable option for managing <strong>uncomplicated hypertension.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Triamterene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Triamterene is a<strong> potassium-sparing diuretic</strong> that is<strong> not</strong> typically used as <strong>first-line treatment for hypertension.</strong> It is often<strong> used in combination</strong> with other <strong>diuretics to prevent hypokalemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Spironolactone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Spironolactone is another <strong>potassium-sparing diuretic </strong>that also<strong> blocks the effects of aldosterone</strong>. While it can be used for <strong>hypertension</strong>, it is usually reserved for cases that are <strong>resistant to other treatments </strong>or for <strong>specific conditions like</strong> <strong>primary hyperaldosteronism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Furosemide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Furosemide is a<strong> loop diuretic</strong> that is primarily used for the treatment of <strong>edema associated with heart failure</strong> or <strong>renal disease.</strong> It is<strong> not</strong> typically used as<strong> first-line treatment for uncomplicated hypertension</strong> due to its<strong> shorter duration of action and </strong>greater risk for<strong> electrolyte imbalances.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to identify the preferred <strong>initial treatment</strong> options for <strong>hypertension. </strong>Thiazide-like diuretics such as <strong>chlorthalidone are recommended as first-line therapy</strong> for most patients with<strong> hypertension</strong> due to their effectiveness in<strong> lowering</strong> <strong>blood pressure and reducing the risk of cardiovascular events. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FIRST LINE DRUGS FOR DIFFERENT PATIENTS WITH HYPERTENSION</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-114419.png\" style=\"height:330px; width:1000px\" /></span></strong></span></span></p>",
    "correct_choice_id": 15051,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3771,
    "choices": [
      {
        "id": 15063,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spontaneous hydrolysis</span></span></span></p>"
      },
      {
        "id": 15064,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rapid metabolism by enzymes in the liver</span></span></span></p>"
      },
      {
        "id": 15065,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uptake in RBC and endothelial cells</span></span></span></p>"
      },
      {
        "id": 15066,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal excretion</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Why does adenosine have a short half-life?</span></span></span></p>",
    "unique_key": "Q3482530",
    "question_audio": null,
    "question_video": null,
    "map_id": 36020,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Uptake in RBC and endothelial cells</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenosine is known to be the shortest-acting anti-arrhythmic drug with a half-life of less than 10 seconds. Its brief duration of action is primarily attributed to its rapid uptake by red blood cells (RBCs) and endothelial cells. Once inside these cells, adenosine is quickly metabolized through two main pathways: phosphorylation and deamination. Phosphorylation, mediated by adenosine kinase, converts adenosine into adenosine monophosphate (AMP), which can then enter various pathways to be used as cellular energy. Deamination, on the other hand, is facilitated by the enzyme adenosine deaminase, leading to the production of inosine, which is further broken down into xanthine and eventually uric acid. The efficient intracellular metabolism of adenosine in these cells ensures that it does not remain active in the bloodstream for long, which is why it has such a short half-life.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Spontaneous hydrolysis:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While spontaneous hydrolysis can occur, it is not the primary reason for adenosine&#39;s short half-life in vivo.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Rapid metabolism by enzymes in the liver:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Although liver enzymes play a role in drug metabolism, in the case of adenosine, the rapid uptake and metabolism by RBCs and endothelial cells are more significant.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Renal excretion:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While renal excretion does remove substances from the blood, adenosine&#39;s short half-life is due more to cellular uptake and metabolism than to excretion by the kidneys.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenosine has a short half-life due to rapid uptake and intracellular metabolism in RBCs and endothelial cells, where it is phosphorylated to AMP or deaminated to eventually form uric acid. Adenosine is also the drug of choice (DOC) for the treatment of paroxysmal supraventricular tachycardia (PSVT).</span></span></span></p>",
    "correct_choice_id": 15065,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3791,
    "choices": [
      {
        "id": 15143,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">a &amp; b</span></span></span></p>"
      },
      {
        "id": 15144,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">b &amp; c</span></span></span></p>"
      },
      {
        "id": 15145,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">c &amp; d</span></span></span></p>"
      },
      {
        "id": 15146,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">b &amp; d</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug obtained from plant (shown in the Figure) is used for treatment of?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/30/picture4_rOVLeTF.jpg\" style=\"height:244px; width:302px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:lower-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myocardial infarction</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malaria</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congestive heart failure</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Arrhythmias</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>",
    "unique_key": "Q5735148",
    "question_audio": null,
    "question_video": null,
    "map_id": 36021,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) b &amp; d</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image is identified as depicting the <strong>bark of the cinchona plant</strong>. From this plant, two significant drugs are derived: <strong>quinine and</strong> <strong>quinidi</strong>ne. Quinine has a<strong> long history </strong>of use in the treatment of <strong>malaria due to its antiprotozoal properties</strong> that are effective<strong> against</strong> the <strong>Plasmodium parasites causing the disease</strong>. <strong>Quinidine,</strong> a <strong>stereoisomer of quinine</strong>, is <strong>utilized </strong>in the <strong>medical field for its</strong> <strong>antiarrhythmic properties</strong> to treat various<strong> cardiac arrhythmias</strong> by acting on the <strong>heart&#39;s electrical conduction system </strong>to <strong>restore</strong> <strong>normal rhythm.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp;</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Myocardial infarction:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Neither <strong>quinine nor quinidine </strong>is primarily used for the treatment of <strong>myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Malaria:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Quinine</strong>, obtained from the <strong>cinchona bark</strong>, is indeed used for the<strong> treatment of malaria.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Congestive heart failure:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Neither quinine nor quinidine</strong> is a <strong>first-line</strong> treatment for<strong> congestive heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Quinine and quinidine, </strong>drugs derived from the<strong> cinchona plant,</strong> are used in the treatment of<strong> malaria and cardiac arrhythmias,</strong> respectively, illustrating the<strong> importance of plant-based compounds</strong> in the <strong>development of medications.</strong></span></span></span></p>",
    "correct_choice_id": 15146,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 3841,
    "choices": [
      {
        "id": 15343,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It should be given in low doses to prevent hyperkalemia</span></span></span></p>"
      },
      {
        "id": 15344,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It affords prognostic benefit in severe heart failure over and above ACEI</span></span></span></p>"
      },
      {
        "id": 15345,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It helps to overcome refractoriness to loop diuretics</span></span></span></p>"
      },
      {
        "id": 15346,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It affords rapid symptomatic relief in CHF patients</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following about the use of spironolactone in congestive heart failure are true except?</span></span></span></p>",
    "unique_key": "Q4404975",
    "question_audio": null,
    "question_video": null,
    "map_id": 36008,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) It affords rapid symptomatic relief in CHF patients</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is<strong> not typically true</strong>. While <strong>spironolactone </strong>can help manage symptoms of<strong> CHF by reducing fluid overload</strong> due to its <strong>diuretic effect,</strong> it <strong>does not</strong> provide rapid <strong>symptomatic relief.</strong> The primary effects of <strong>spironolactone in CHF</strong> are seen over a<strong> longer</strong> term, where it helps to manage<strong> fluid retention and provides benefits in terms of morbidity and mortality.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Based on these points, the statement that is <strong>not true</strong> about the <strong>use of spironolactone in CHF</strong> is <strong>d. It affords rapid symptomatic relief in CHF patients</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>It should be given in low doses to prevent hyperkalemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is<strong> true.</strong> Spironolactone is a<strong> potassium-sparing diuretic</strong>, and one of its potential side effects is <strong>hyperkalemia (high blood potassium levels). </strong>Therefore, it is typically started at a<strong> low dose to minimize this risk.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>It affords prognostic benefit in severe HF over and above ACEI.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is<strong> true</strong>. Spironolactone has been shown to provide a<strong> prognostic benefit </strong>in patients with <strong>severe heart</strong> <strong>failure, reducing morbidity and mortality</strong> when added to <strong>standard therapy, including ACE inhibitors (ACEIs).</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>It helps to overcome refractoriness to loop diuretics.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. Spironolactone can be used in <strong>combination with loop diuretics </strong>to overcome <strong>diuretic resistance </strong>in <strong>CHF</strong>. L<strong>oop diuretics </strong>can lead to<strong> increased renal potassium and magnesium loss, </strong>and adding a <strong>potassium-sparing agent</strong> like<strong> spironolactone </strong>can help<strong> counteract this effect and enhance diuretic response.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Current evidence suggests the following regarding aldosterone receptor antagonist (spironolactone and eplerenone) therapy in CHF:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is indicated as<strong> add-on therapy to ACE inhibitors + other drugs</strong> in <strong>moderate-to-severe CHF.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can <strong>retard disease progression, reduce episodes of decompensation and death </strong>due to<strong> heart failure</strong> as well as <strong>sudden</strong> c<strong>ardiac deaths</strong>, over and above the <strong>protection afforded by ACE inhibitors/ARBs &plusmn; &beta; blockers.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only <strong>low doses (12.5&ndash;25 mg/day) </strong>of spironolactone should be used to <strong>avoid hyperkalemia;</strong> particularly because of <strong>concurrent ACE inhibitor/ARB therapy.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It may help <strong>restoration of diuretic response to furosemide</strong> when <strong>refractoriness has developed.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 15346,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3846,
    "choices": [
      {
        "id": 15363,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduction of after load</span></span></span></p>"
      },
      {
        "id": 15364,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduction of heart rate and cardiac MVO2</span></span></span></p>"
      },
      {
        "id": 15365,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduction of preload and cardiac MVO2</span></span></span></p>"
      },
      {
        "id": 15366,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase preload with decrease in cardiac MVO2</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac oxygen demand (MVO2) must be reduced in angina pectoris. The therapeutic rationale for using SL nitroglycerine is based on: </span></span></span></p>",
    "unique_key": "Q3997576",
    "question_audio": null,
    "question_video": null,
    "map_id": 36010,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Reduction of preload and cardiac MVO2</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sublingual (SL) nitroglycerine</strong> acts primarily by<strong> dilating venous capacitance vessels,</strong> leading to a <strong>reduction in preload. </strong>By<strong> reducing preload, nitroglycerine decreases ventricular filling pressure and volume</strong>, which in turn <strong>reduces myocardial</strong> <strong>oxygen demand (MVO2</strong>). This mechanism helps <strong>alleviate angina pectoris by decreasing the workload </strong>on the heart and<strong> improving myocardial oxygen supply-demand balance.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Reduction of afterload:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While <strong>nitroglycerine</strong> may have<strong> some effect</strong> on<strong> reducing afterload </strong>due to its <strong>arterial vasodilatory</strong> <strong>properties</strong>, its<strong> primary mechanism of action</strong> is the <strong>reduction of preload.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Reduction of heart rate and cardiac MVO2:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Nitroglycerine</strong> may have a <strong>mild effect on heart rate</strong>, but its primary mechanism of action is<strong> not related to heart rate reduction.</strong> It mainly <strong>reduces preload,</strong> which <strong>indirectly decreases cardiac MVO2.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Increase preload with decrease in cardiac MVO2:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Increasing preload </strong>would typically <strong>increase cardiac workload and</strong> <strong>oxygen demand </strong>rather than<strong> decrease it. </strong>This option <strong>contradicts</strong> the therapeutic rationale for using <strong>nitroglycerine in angina pectoris.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>therapeutic rationale </strong>for using <strong>sublingual nitroglycerine</strong> in the management of<strong> angina</strong> <strong>pectoris</strong>. By<strong> reducing preload, </strong>nitroglycerine <strong>decreases myocardial oxygen demand,</strong> <strong>providing symptomatic relief</strong> in patients with <strong>angina</strong>. Understanding the <strong>mechanisms of action of nitroglycerine</strong> is essential for appropriate<strong> prescribing and management</strong> of <strong>angina episode</strong>s.</span></span></span></p>",
    "correct_choice_id": 15365,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3821,
    "choices": [
      {
        "id": 15263,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These should be started at a very low dose and slowly titrated upwards</span></span></span></p>"
      },
      {
        "id": 15264,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carvedilol is the most widely used &beta; blocker</span></span></span></p>"
      },
      {
        "id": 15265,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These are drug of choice in acute decompensated heart failure</span></span></span></p>"
      },
      {
        "id": 15266,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These can reduce mortality in CHF patients</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT true about the use of &beta; blockers in CHF?</span></span></span></p>",
    "unique_key": "Q3002626",
    "question_audio": null,
    "question_video": null,
    "map_id": 36027,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) These are drug of choice in acute decompensated heart failure</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Beta blockers</strong> are not the drug of choice in<strong> acute decompensated heart failure.</strong> In fact, they are <strong>contraindicated</strong> in this condition due to <strong>their potential to worsen the hemodynamic status.</strong> In <strong>acute decompensated heart failure</strong>, the goal is to<strong> quickly improve cardiac</strong> <strong>output and relieve symptoms,</strong> and the<strong> negative inotropic effects of beta blockers </strong>can <strong>counteract this goal.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. These should be started at a very low dose and slowly titrated upwards:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>correct </strong>and a key principle in the <strong>chronic</strong> management of <strong>CHF</strong>. Beta blockers need to be started at<strong> low doses to avoid abrupt changes in cardiac function</strong> and allow for patient tolerance.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Carvedilol is the most widely used &beta; blocker:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>carvedilol </strong>is one of the commonly used <strong>beta blockers in CHF,</strong> saying it is &quot;<strong>the most widely used</strong>&quot; may <strong>not be true in all settings,</strong> as <strong>metoprolol and bisoprolol </strong>are<strong> also commonly prescribed.</strong> However, this statement is generally accepted in practice.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. These can reduce mortality in CHF patients:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>true</strong>. <strong>Beta blockers</strong> have been shown to<strong> decrease mortality in chronic</strong> <strong>CHF </strong>by <strong>improving left ventricular function</strong>, <strong>reducing arrhythmias, and limiting cardiac remodeling.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><strong><u> </u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Beta blockers</strong> should <strong>not</strong> be used as the <strong>drug of choice</strong> in <strong>acute decompensated heart failure</strong> but are essential for the management of<strong> chronic CHF</strong>, where they have been shown to <strong>reduce mortality and morbidity.</strong></span></span></span></p>",
    "correct_choice_id": 15265,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3583,
    "choices": [
      {
        "id": 14311,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Losartan</span></span></span></p>"
      },
      {
        "id": 14312,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Telmisartan</span></span></span></p>"
      },
      {
        "id": 14313,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Candesartan</span></span></span></p>"
      },
      {
        "id": 14314,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Olmesartan</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Angiotensin receptor blocker which blocks thromboxane A2 receptor is?</span></span></span></p>",
    "unique_key": "Q3535972",
    "question_audio": null,
    "question_video": null,
    "map_id": 36030,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Losartan</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Losartan </strong>is the correct answer because it is<strong> not </strong>only an <strong>angiotensin receptor blocker (ARB)</strong> but also a <strong>competitive antagonist </strong>of the <strong>thromboxane A2 receptor</strong>. This <strong>dual action means</strong> that<strong> Losartan can block the effects of thromboxane A2</strong>, leading to an <strong>attenuation</strong> of <strong>platelet aggregation</strong>. Additionally, the<strong> metabolite of Losartan</strong> has the ability to <strong>reduce COX-2 mRNA upregulation</strong> and <strong>COX-dependent prostaglandin generation,</strong> which further contributes to its<strong> antiplatelet effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Telmisartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>because <strong>Telmisartan is known as a partial agonist of peroxisome proliferator-activated receptor</strong> <strong>gamma (PPAR-&gamma;),</strong> which differentiates it from Losartan and <strong>does not</strong> confer the ability to<strong> block the thromboxane A2 receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Candesartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as <strong>Candesartan </strong>is an <strong>inactive ester </strong>prodrug that <strong>does not</strong> possess the ability to <strong>block the</strong> <strong>thromboxane A2 receptor.</strong> It is<strong> hydrolyzed</strong> to<strong> its active form </strong>within the body, which <strong>acts selectively </strong>on the<strong> angiotensin receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Olmesartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> for this question since <strong>Olmesartan, </strong>while also being an<strong> inactive ester prodrug hydrolyzed </strong>to its <strong>active form</strong>, <strong>does not block the thromboxane A2 receptor.</strong> It is <strong>cleared by renal elimination</strong> and<strong> biliary excretion</strong> and <strong>does not</strong> require dose adjustment in patients with <strong>mild-to-moderate renal or hepatic impairment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Losartan</strong> is unique among <strong>angiotensin receptor blockers </strong>in that it also <strong>competitively antagonizes</strong> the <strong>thromboxane A2 receptor,</strong> contributing to its <strong>antiplatelet effects.</strong></span></span></span></p>",
    "correct_choice_id": 14311,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3850,
    "choices": [
      {
        "id": 15379,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aliskiren</span></span></span></p>"
      },
      {
        "id": 15380,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Losartan</span></span></span></p>"
      },
      {
        "id": 15381,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Perindopril</span></span></span></p>"
      },
      {
        "id": 15382,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vernakalant</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a direct renin inhibitor? </span></span></span></p>",
    "unique_key": "Q4577835",
    "question_audio": null,
    "question_video": null,
    "map_id": 36011,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Aliskiren</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aliskiren is a novel class of antihypertensive drug</strong> that works by directly<strong> inhibiting renin,</strong> an enzyme responsible for the conversion of <strong>angiotensinogen to angiotensin I (Ang I).</strong> This action effectively <strong>inhibits the renin-angiotensin-aldosterone system (RAAS)</strong> at its <strong>earliest step</strong>. Aliskiren is a<strong> low-molecular-weight, non-peptide molecule</strong> that acts as a <strong>potent competitive inhibitor of renin, reducing the production of angiotensin II (Ang II)</strong> as a result of the <strong>blocked conversion of angiotensinogen to Ang I.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Losartan:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Losartan is an<strong> angiotensin II receptor blocker (ARB),</strong> which works further<strong> downstream in the RAAS pathway </strong>by <strong>blocking the angiotensin II type 1 receptors on blood vessels,</strong> leading to<strong> vasodilation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Perindopril:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Perindopril is an <strong>angiotensin-converting enzyme (ACE) inhibitor</strong>. It <strong>prevents </strong>the conversion of <strong>angiotensin I to</strong> <strong>angiotensin II </strong>by inhibiting the <strong>ACE enzyme.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Vernakalant:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Vernakalant is<strong> not </strong>related to the <strong>RAAS pathway</strong>; it is a<strong> class III antiarrhythmic agent</strong> that acts as a <strong>multiple</strong> <strong>ion channel blocke</strong>r, particularly affecting<strong> atrial cells, </strong>and is used to treat certain<strong> types of arrhythmias.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aliskiren</strong> is the only direct <strong>renin inhibitor </strong>among the options listed, acting at the<strong> rate-limiting step of the RAAS pathway</strong> by <strong>inhibiting the conversion of angiotensinogen to angiotensin I.</strong></span></span></span></p>",
    "correct_choice_id": 15379,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3862,
    "choices": [
      {
        "id": 15427,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydralazine</span></span></span></p>"
      },
      {
        "id": 15428,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol </span></span></span></p>"
      },
      {
        "id": 15429,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazide diuretic </span></span></span></p>"
      },
      {
        "id": 15430,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nifedipine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 33-year-old man is diagnosed with essential hypertension. He is started on an anti-hypertensive medication. After 6 weeks, he notes fatigue, rash over his face, joint aches, and effusions. A serum antinuclear antibody (ANA) test is positive. Which of the following is the most likely agent person was prescribed? </span></span></span></p>",
    "unique_key": "Q4786450",
    "question_audio": null,
    "question_video": null,
    "map_id": 36014,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Hydralazine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s symptoms of <strong>fatigue, malar rash, joint pain, effusions</strong>, and a <strong>positive ANA test </strong>suggest the development of a<strong> drug-induced lupus erythematosus (SLE) </strong>like syndrome.<strong> Hydralazine</strong> is known to be associated with the <strong>development of drug-induced SLE.</strong> The condition is<strong> similar to idiopathic SLE </strong>and includes symptoms such as those described. <strong>Drug-induced SLE is reversible </strong>on <strong>stopping</strong> the<strong> offending agent.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Propranolol:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Beta-blockers</strong> like propranolol are <strong>not </strong>commonly associated with inducing a<strong> lupus-like syndrome.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Thiazide diuretic:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazide diuretics have <strong>various side effects</strong> but are<strong> not </strong>typically known to cause <strong>drug-induced lupus.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.&nbsp; Nifedipine:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nifedipine, a<strong> calcium channel blocker</strong>, is <strong>not </strong>associated with <strong>lupus-like symptoms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hydralazine</strong> is associated with the<strong> development of a lupus-like syndrome, </strong>which is characterized by symptoms such as<strong> rash, joint</strong> <strong>pain, fatigue, and positive ANA,</strong> and it is <strong>one of the drugs</strong> that can<strong> induce</strong> this condition, summarized by the acronym <strong>&quot;SHIP&quot;</strong> for <strong>sulfonamides, hydralazine, isoniazid, and procainamide.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The drugs causing <strong>SLE like syndrome</strong> include:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">S: S</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ulfonamides (including dapsone)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">H: H</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ydralazine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">I: I</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">soniazid</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">P: P</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">rocainamide</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All<strong> SHIP drugs</strong> are <strong>metabolized by acetylation.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>",
    "correct_choice_id": 15427,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3868,
    "choices": [
      {
        "id": 15451,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triamterene </span></span></span></p>"
      },
      {
        "id": 15452,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atenolol</span></span></span></p>"
      },
      {
        "id": 15453,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clarithromycin</span></span></span></p>"
      },
      {
        "id": 15454,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">KCI</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient on digoxin therapy had a level of 1 ng/ml. He was receiving several other drugs and presented 2 months later with flattening of T waves in ECG. Now the plasma level of digoxin is 3.8 ng/ml. Which of the following drug is likely to be responsible? </span></span></span></p>",
    "unique_key": "Q8840588",
    "question_audio": null,
    "question_video": null,
    "map_id": 36016,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Clarithromycin</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clarithromycin is a<strong> macrolide antibiotic </strong>known to <strong>inhibit the P-glycoprotein transporter, </strong>which plays a role in the <strong>renal excretion of</strong> <strong>digoxin.</strong> <strong>Inhibition</strong> <strong>of </strong>this transporter <strong>leads to decreased renal clearance of digoxin,</strong> resulting in <strong>elevated plasma levels</strong> and <strong>potential digoxin toxicity. Flattening </strong>of <strong>T waves</strong> on ECG is a common manifestation of <strong>digoxin toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Triamterene:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triamterene is a <strong>potassium-sparing diuretic </strong>that can <strong>increase digoxin levels</strong> by <strong>reducing its renal clearance.</strong> However, the<strong> extent of increase</strong> observed in this case is <strong>less </strong>commonly associated with <strong>triamterene.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Atenolol:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atenolol, a<strong> beta-blocker, </strong>can<strong> increase digoxin levels </strong>by <strong>delaying its elimination</strong>. However, the <strong>degree of increase</strong> seen here is less characteristic of atenolol&#39;s interaction with digoxin.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. KCl:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Potassium chloride supplementation </strong>can potentiate the effects of <strong>digoxin</strong>, potentially leading to<strong> toxicity. </strong>However, it typically <strong>does not </strong>cause such a significant<strong> increase in digoxin levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recognizing <strong>drug interactions</strong> that impact <strong>digoxin levels</strong> is crucial for <strong>preventing digoxin toxicity </strong>in patients receiving<strong> concurrent</strong> <strong>therapy</strong>.<strong> Vigilance </strong>and <strong>close monitoring of digoxin levels </strong>are essential to ensure <strong>patient safety.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">INTERACTIONS OF DIGOXIN</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hypokalemia, hypomagnesemia, and hypercalcemia</strong> may precipitate digoxin toxicity.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs <strong>causing digoxin</strong> <strong>toxicity</strong> include:</span></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"margin-left:40px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazides</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clarithromycin</span></span></span></li>\r\n</ul>\r\n\r\n<ol start=\"3\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Renal failure </strong>predisposes to<strong> digoxin toxicity.</strong></span></span></span></li>\r\n</ol>",
    "correct_choice_id": 15453,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 3869,
    "choices": [
      {
        "id": 15455,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methyldopa</span></span></span></p>"
      },
      {
        "id": 15456,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Labetalol</span></span></span></p>"
      },
      {
        "id": 15457,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lisinopril</span></span></span></p>"
      },
      {
        "id": 15458,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nifedipine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 26-year-old female came to hospital for preconception counseling. Patient is a known hypertensive compliant to drug therapy. Which of the following drugs will you advise to stop?</span></span></span></p>",
    "unique_key": "Q3371532",
    "question_audio": null,
    "question_video": null,
    "map_id": 36017,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Lisinopril</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>ACE Inhibitors (like lisinopril) and ARBs (like telmisartan) </strong>are known to be<strong> teratogenic </strong>and should be <strong>avoided if pregnancy </strong>is under <strong>consideration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Methyldopa:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Methyldopa is<strong> commonly used in pregnancy for hypertension </strong>and is considered<strong> safe. </strong>It is often continued during pregnancy if the patient is<strong> well-controlled.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Labetalol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Labetalol is another <strong>antihypertensive agent </strong>commonly used<strong> during pregnancy</strong>. It has a<strong> good safety profile</strong> and is often continued if the <strong>patient is well-controlled.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Nifedipine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Nifedipine is also considered<strong> safe for use during pregnancy </strong>and is commonly <strong>prescribed for hypertension </strong>in <strong>pregnant women.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the <strong>safety profiles of antihypertensive medications </strong>during <strong>pregnancy</strong> is essential for <strong>preconception counseling.</strong> <strong>Lisinopril is contraindicated during pregnancy</strong> due to its association with <strong>fetal malformations,</strong> particularly during the <strong>second and</strong> <strong>third trimesters</strong>. It is important to<strong> discontinue</strong> potentially<strong> harmful medications before conception</strong> to<strong> minimize risks to both </strong>the <strong>mother and the developing fetus.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SAFE ANTI-HYPERTENSIVES IN PREGNANCY</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">etter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;<strong>B</strong>eta blockers (Cardio selective and Labetalol)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">M</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">other&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;<strong>Methyldopa</strong> </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -<strong>C</strong>lonidine </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">uring&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -<strong>D</strong>ihydropyridine CCB (sustained release nifedipine, amlodipine)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">H</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ypertensive&nbsp;&nbsp; -&nbsp;<strong>H</strong>ydralazine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">P</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">regnancy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;<strong>P</strong>razosin (and other alpha blockers)</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 15457,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 3755,
    "choices": [
      {
        "id": 14999,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
      },
      {
        "id": 15000,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
      },
      {
        "id": 15001,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ciprofloxacin</span></span></span></p>"
      },
      {
        "id": 15002,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs can result in prolongation of QT interval in ECG?</span></span></span></p>",
    "unique_key": "Q1108176",
    "question_audio": null,
    "question_video": null,
    "map_id": 36018,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Quinidine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Quinidine</strong> is a<strong> class Ia anti-arrhythmic drug</strong> that acts by<strong> blocking Na+ (sodium) and K+ (potassium) channels</strong>. The blocking of <strong>potassium channels </strong>is particularly important in the context of the question as it can affect the<strong> repolarization phase of the cardiac</strong> <strong>action potential, </strong>which is reflected as<strong> QT interval on an electrocardiogram (ECG). Prolonged repolarization</strong> leads to a<strong> prolonged QT</strong> <strong>interval</strong>, which can predispose to a <strong>type of ventricular tachycardia</strong> called <strong>Torsades de Pointes</strong>, a potentially <strong>life-threatening</strong> <strong>condition.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Lignocaine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Lignocaine (also known as lidocaine) is a<strong> class Ib anti-arrhythmic drug</strong> that predominantly <strong>blocks Na+ channels</strong> and is<strong> less </strong>likely to cause <strong>QT prolongation </strong>as its action is<strong> more specific to the fast sodium channels</strong> and it actually tends to <strong>shorten the action potential duration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ciprofloxacin:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ciprofloxacin is a <strong>fluoroquinolone antibiotic</strong>. Although fluoroquinolones like <strong>sparfloxacin, levofloxacin, and</strong> <strong>moxifloxacin</strong> are associated with <strong>QT prolongation, ciprofloxacin is less</strong> implicated in causing this <strong>adverse effect</strong> when compared to other drugs in its class.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Propranolol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Propranolol is a<strong> non-selective beta-blocker</strong> and is <strong>not</strong> commonly associated with<strong> QT prolongation</strong>. It acts on the <strong>beta-adrenergic receptors </strong>and can affect<strong> heart rate and contractility</strong> but <strong>not</strong> typically the <strong>QT interval.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Quinidine,</strong> a <strong>class Ia anti-arrhythmic drug</strong>, can cause<strong> QT interval prolongation on an ECG</strong> due to its<strong> blockade of potassium channels,</strong> which affects the<strong> repolarization phase of the cardiac action potential.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-113043.png\" style=\"height:486px; width:1000px\" /></span></span></span></p>",
    "correct_choice_id": 14999,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3798,
    "choices": [
      {
        "id": 15171,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpha 1</span></span></span></p>"
      },
      {
        "id": 15172,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpha 2</span></span></span></p>"
      },
      {
        "id": 15173,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta 1</span></span></span></p>"
      },
      {
        "id": 15174,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta 2</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Inotropic drugs act by stimulating which of the following receptors? </span></span></span></span></span></p>",
    "unique_key": "Q4079299",
    "question_audio": null,
    "question_video": null,
    "map_id": 36024,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Beta 1</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Inotropic drugs</strong> often act by <strong>stimulating beta 1 adrenergic receptors</strong>. Beta 1 receptors are <strong>primarily found in the heart, </strong>and when they are stimulated, they<strong> increase myocardial contractility </strong>(the <strong>force of contraction</strong>) and <strong>heart rate. </strong>This <strong>action is beneficial </strong>in treating certain conditions like <strong>heart failure,</strong> where an<strong> increase in cardiac output is needed.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational goal is to understand the<strong> mechanism of action </strong>of different<strong> inotropic drugs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">INOTROPICS DRUGS</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:upper-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Beta 1 agonists</span></strong></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"margin-left:40px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Dopamine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dobutamine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nor-adrenaline</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Isoprenaline</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol start=\"2\" style=\"list-style-type:upper-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phosphodiesterase inhibitors</span></strong></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"margin-left:40px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inamrinone</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Milrinone</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levosimendan</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol start=\"3\" style=\"list-style-type:upper-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cardiac glycosides</span></strong></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"margin-left:40px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Digoxin</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Digitoxin (withdrawn now)</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 15173,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 43289,
    "choices": [
      {
        "id": 172823,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of HMG-CoA reductase </span></span></span></p>"
      },
      {
        "id": 172824,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of cholesterol absorption in the small intestine </span></span></span></p>"
      },
      {
        "id": 172825,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of bile acid synthesis in the liver </span></span></span></p>"
      },
      {
        "id": 172826,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of lipoprotein lipase activity</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the mechanism of action of ezetimibe for the treatment of hypercholesterolemia?</span></span></span></p>",
    "unique_key": "Q1024668",
    "question_audio": null,
    "question_video": null,
    "map_id": 36015,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Inhibition of cholesterol absorption in the small intestine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ezetimibe</strong> specifically targets the <strong>NPC1L1 (Niemann-Pick C1-Like 1) protein,</strong> which is involved in the<strong> intestinal absorption </strong>of <strong>cholesterol.</strong> By<strong> inhibiting NPC1L1,</strong> <strong>ezetimibe reduces the uptake of cholesterol in the small intestine</strong>, leading to a <strong>decrease in the</strong> <strong>amount of cholesterol delivered to the liver. </strong>This results in a<strong> reduction of hepatic cholesterol stores </strong>and an <strong>increase in clearance of</strong> <strong>cholesterol</strong> from the <strong>blood</strong>; consequently,<strong> LDL cholesterol </strong>levels in the <strong>bloodstream decrease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Inhibition of HMG-CoA reductase:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is the mechanism of action for <strong>statins, not ezetimibe. Statins inhibit the rate-</strong>l<strong>imiting step in cholesterol synthesis in the liver.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Inhibition of bile acid synthesis in the liver:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Bile acid sequestrants </strong>work by this mechanism. They bind<strong> bile acids</strong> in the <strong>intestine, </strong>leading to<strong> increased excretion of cholesterol in the feces.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Inhibition of lipoprotein lipase activity:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Inhibiting lipoprotein lipase</strong> would prevent the<strong> breakdown of triglycerides, </strong>not cholesterol. This is<strong> not a mechanism</strong> associated with<strong> ezetimibe.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ezetimibe</strong> <strong>reduces LDL cholesterol by inhibiting the absorption of cholesterol</strong> in the small intestine through its action on the<strong> NPC1L1</strong> <strong>protein.</strong></span></span></span></p>",
    "correct_choice_id": 172824,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3611,
    "choices": [
      {
        "id": 14423,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stable angina</span></span></span></p>"
      },
      {
        "id": 14424,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prerenal azotemia</span></span></span></p>"
      },
      {
        "id": 14425,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alzheimer&rsquo;s disease</span></span></span></p>"
      },
      {
        "id": 14426,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Smoking cessation</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivabradine is a drug that has been used in clinical practice for few years now. It is indicated for the management of which of the following diseases?</span></span></span></p>",
    "unique_key": "Q7754999",
    "question_audio": null,
    "question_video": null,
    "map_id": 36044,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Stable angina&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ivabradine </strong>selectively<strong> inhibits</strong> the <strong>funny current (If)</strong> in the<strong> sinoatrial (SA) node</strong>, which is a <strong>pacemaker current</strong> that contributes to the <strong>slow diastolic depolarization (phase 4) of the cardiac cycle. </strong>By <strong>inhibiting this current,</strong> <strong>ivabradine</strong> effectively reduces the<strong> heart rate</strong> <strong>without</strong> affecting<strong> myocardial contractility or intracardiac conduction. </strong>A <strong>major determinant of angina,</strong> particularly <strong>stable angina</strong>, is <strong>heart rate. </strong>By <strong>lowering the heart rate</strong>, ivabradine helps to manage <strong>stable angina by reducing myocardial oxygen demand.</strong> It is as efficacious as <strong>calcium channel blockers and beta blockers in lowering heart rate</strong>. <strong>Ivabradine</strong> has also <strong>gained approval for use </strong>in the treatment of<strong> congestive heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Prerenal azotemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> as <strong>prerenal azotemia</strong> is related to<strong> kidney function</strong> and <strong>ivabradine does not </strong>have a role in its <strong>treatment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Alzheimer&rsquo;s disease:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because Alzheimer&rsquo;s disease is a<strong> neurodegenerative condition</strong> and <strong>ivabradine is not</strong> indicated for its <strong>treatment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Smoking cessation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> as<strong> ivabradine </strong>is <strong>not </strong>used in <strong>smoking cessation</strong>; it is a <strong>cardiac medication </strong>used for <strong>heart rate</strong> <strong>control.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ivabradine</strong> is indicated for the<strong> management of stable angina and congestive heart failure</strong>. It works by<strong> inhibiting the funny current </strong>in the<strong> SA node</strong>, leading to a <strong>reduction in heart rate,</strong> which is a key therapeutic target in managing these conditions.</span></span></span></p>",
    "correct_choice_id": 14423,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3635,
    "choices": [
      {
        "id": 14519,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertensive emergencies</span></span></span></p>"
      },
      {
        "id": 14520,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congestive heart failure</span></span></span></p>"
      },
      {
        "id": 14521,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Migraine prophylaxis</span></span></span></p>"
      },
      {
        "id": 14522,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tachyarrhythmias</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fenoldopam is used in the management of? </span></span></p>",
    "unique_key": "Q1820733",
    "question_audio": null,
    "question_video": null,
    "map_id": 36038,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Hypertensive emergencies </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Fenoldopam </strong>is used in the management of <strong>hypertensive emergencies.</strong> It is a <strong>selective dopamine D1 receptor agonist</strong> that induces <strong>vasodilation of peripheral arterie</strong>s, leading to a <strong>rapid decrease in blood press</strong>ure. One of the advantages of <strong>fenoldopam is its ability</strong> to<strong> enhance renal perfusion</strong>, which is beneficial in<strong> hypertensive emergencies</strong> where<strong> kidney function </strong>may be <strong>compromised.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Congestive heart failure:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Fenoldopam </strong>is <strong>not </strong>typically used in the management of<strong> congestive heart failure (CHF). </strong>Drugs commonly used in <strong>CHF include ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists</strong>, which work by different mechanisms to <strong>reduce the workload on the heart </strong>and <strong>improve cardiac output</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Migraine prophylaxis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Fenoldopam </strong>is <strong>not </strong>used for <strong>migraine prophylaxis</strong>. Medications for migraine prevention include <strong>beta-blockers (such as propranolol), calcium channel blockers, antidepressants, and antiepileptic drugs</strong>, which have different mechanisms of action aimed at <strong>reducing the frequency and severity of migraine attacks</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Tachyarrhythmias:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Fenoldopam </strong>is<strong> not </strong>indicated for the treatment of <strong>tachyarrhythmias. Drugs used </strong>to manage tachyarrhythmias include <strong>beta-blockers, calcium channel blockers, antiarrhythmic agents, and sometimes digoxin</strong>, depending on the<strong> type and cause of the arrhythmia. </strong>These medications work by<strong> modulating cardiac electrical activity </strong>to <strong>normalize heart rhythm</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>specific indications for fenoldopam, </strong>particularly its role in <strong>managing hypertensive emergencies </strong>due to <strong>its vasodilatory effects </strong>and positive impact on <strong>renal perfusion</strong>. Additionally, recognizing that <strong>fenoldopam is not </strong>indicated for<strong> congestive heart failure, migraine prophylaxis, or tachyarrhythmias </strong>underscores the importance of selecting appropriate medications based on the clinical condition being treated.</span></span></p>",
    "correct_choice_id": 14519,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3654,
    "choices": [
      {
        "id": 14595,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ventricular bigeminy</span></span></span></p>"
      },
      {
        "id": 14596,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paroxysmal atrial tachycardia with fast ventricular rate</span></span></span></p>"
      },
      {
        "id": 14597,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Regularization of atrial fibrillation</span></span></span></p>"
      },
      {
        "id": 14598,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bidirectional ventricular tachycardia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following are seen in digitalis toxicity except: </span></span></p>",
    "unique_key": "Q1185413",
    "question_audio": null,
    "question_video": null,
    "map_id": 36035,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Paroxysmal atrial tachycardia with fast ventricular rate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Digitalis toxicity does not</strong> typically cause <strong>paroxysmal atrial tachycardia </strong>with a <strong>fast ventricular rate.</strong> Instead, <strong>digitalis</strong> characteristically induces <strong>atrial tachycardia with atrioventricular (AV) block, </strong>leading to a <strong>slower ventricular response,</strong> not a fast one. <strong>Ventricular premature beats and bigeminy </strong>are common<strong> arrhythmias resulting from digitalis toxicity</strong>. Digitalis toxicity can also lead to the r<strong>egularization of atrial fibrillation (AF), </strong>which implies the <strong>presence of complete heart block </strong>and results in the<strong> ventricles</strong> <strong>pacing at their intrinsic rate,</strong> leading to a<strong> regular rhythm</strong>.<strong> Bidirectional ventricular tachycardia,</strong> an <strong>unusual tachyarrhythmia</strong>, can also be associated with<strong> digitalis toxicity </strong>and is characterized by alternation of the <strong>QRS complex axis between beats.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Ventricular bigeminy:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Seen with <strong>digitalis toxicity </strong>as it causes<strong> increased ventricular ectopy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Regularization of atrial fibrillation:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Suggestive of <strong>digitalis toxicity</strong> where there is an <strong>AV block </strong>with a<strong> regular ventricular</strong> <strong>rate.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bidirectional ventricular tachycardia:</strong> Associated with <strong>digitalis toxicity </strong>and can manifest in the context of <strong>severe structural</strong> <strong>heart disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In<strong> digitalis toxicity,</strong> you would expect to see <strong>arrhythmias such as ventricular bigeminy, regularization of AF due to AV block,</strong> and <strong>bidirectional ventricular tachycardia,</strong> but <strong>not paroxysmal atrial tachycardia</strong> with a <strong>fast ventricular rate</strong></span></span></span></p>",
    "correct_choice_id": 14596,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 3854,
    "choices": [
      {
        "id": 15395,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone </span></span></span></p>"
      },
      {
        "id": 15396,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sotalol</span></span></span></p>"
      },
      {
        "id": 15397,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine </span></span></span></p>"
      },
      {
        "id": 15398,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following antiarrhythmic drug is contraindicated in a patient with interstitial lung disease? </span></span></span></p>",
    "unique_key": "Q7298812",
    "question_audio": null,
    "question_video": null,
    "map_id": 36036,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Amiodarone</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiodarone</strong> is a<strong> class III antiarrhythmic agent </strong>that has a <strong>well-documented side effect profile, </strong>including <strong>pulmonary toxicity.</strong> The drug can <strong>cause pulmonary alveolitis and fibrosis</strong>, which are <strong>particularly serious </strong>and can be<strong> life-threatening</strong>. Because of its<strong> potential</strong> <strong>to exacerbate pulmonary conditions</strong>, it is <strong>contraindicated </strong>in patients with<strong> existing interstitial lung disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sotalol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Sotalol is also a <strong>class III antiarrhythmic drug</strong> but <strong>does not </strong>carry the same risk for inducing <strong>pulmonary toxicity as</strong> <strong>amiodarone.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Quinidine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Quinidine is a<strong> class Ia antiarrhythmic drug</strong> and is <strong>not </strong>associated with<strong> interstitial lung disease</strong> as a side effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Lignocaine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Lignocaine (lidocaine) is a<strong> class Ib antiarrhythmic </strong>drug used mainly in <strong>acute settings for ventricular</strong> <strong>arrhythmias </strong>and <strong>does not</strong> have<strong> pulmonary toxicity akin to amiodarone.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiodarone,</strong> while effective as a <strong>broad-spectrum antiarrhythmic agent</strong>, is <strong>contraindicated in patients</strong> with <strong>interstitial lung disease</strong> because of its serious <strong>side effect of pulmonary alveolitis and fibrosis.</strong></span></span></span></p>",
    "correct_choice_id": 15395,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 3769,
    "choices": [
      {
        "id": 15055,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of guanylyl cyclase and decrease in cGMP</span></span></span></p>"
      },
      {
        "id": 15056,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of guanylyl cyclase and increase in cGMP</span></span></span></p>"
      },
      {
        "id": 15057,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of guanylyl cyclase and decrease in cAMP</span></span></span></p>"
      },
      {
        "id": 15058,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of guanylyl cyclase and increase in cAMP</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nitrates are an important group of vasodilators used for angina and hypertension. These drugs primarily act by:</span></span></span></p>",
    "unique_key": "Q5928079",
    "question_audio": null,
    "question_video": null,
    "map_id": 36042,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Activation of guanylyl cyclase and increase in cGMP</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nitrates, such as nitroglycerin,</strong> are<strong> vasodilators </strong>that are commonly used in the management of <strong>angina pectoris </strong>and certain forms of <strong>hypertension</strong>. They<strong> primarily act</strong> by<strong> donating nitric oxide (NO)</strong>, which then<strong> activates guanylyl cyclase in vascular smooth muscle</strong> <strong>cells</strong>. This<strong> activation</strong> leads to an<strong> increase in the intracellular levels of cyclic guanosine monophosphate (cGMP)</strong>. <strong>Elevated cGMP</strong> levels result in the <strong>relaxation of smooth muscle cells and vasodilation, </strong>which <strong>decreases venous return (preload)</strong> and<strong> reduces</strong> <strong>myocardial oxygen demand,</strong> thereby <strong>alleviating anginal symptoms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>mechanism of action of nitrates </strong>in the treatment of <strong>angina and hypertension. </strong>Knowledge that<strong> nitrates increase cGMP levels</strong> through the<strong> activation of guanylyl cyclase </strong>is fundamental in understanding how these drugs induce<strong> vasodilation </strong>and <strong>relieve symptoms associated with ischemic heart disease</strong>. This mechanism is also the basis for the <strong>use of</strong> <strong>nitrates </strong>in other conditions where<strong> vasodilation is beneficial.</strong></span></span></span></p>",
    "correct_choice_id": 15056,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 3775,
    "choices": [
      {
        "id": 15079,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methyl Dopa</span></span></span></p>"
      },
      {
        "id": 15080,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Minoxidil</span></span></span></p>"
      },
      {
        "id": 15081,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Captopril</span></span></span></p>"
      },
      {
        "id": 15082,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fenoldopam</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old female treated with an antihypertensive drug and presented with the following features shown in figure. Likely agent is? </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-1px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/41.jpg\" style=\"height:169px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q7827388",
    "question_audio": null,
    "question_video": null,
    "map_id": 36045,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Minoxidil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given image shows the<strong> presence of hirsutism,</strong> which is characterized by <strong>excessive, male-pattern hair growth in female. Minoxidil</strong>, when used systemically as an <strong>antihypertensive medication</strong>, can cause <strong>hirsutism as a side effect</strong>. This excessive <strong>hair</strong> <strong>growth </strong>occurs due to the<strong> drug&#39;s effect on hair follicles, </strong>stimulating them to <strong>shift from the telogen phase (resting phase) to the</strong> <strong>anagen phase (growth phase)</strong>. While<strong> topical minoxidil</strong> is used to <strong>treat hair loss by exploiting this side effect</strong>, <strong>systemic use for</strong> <strong>hypertension</strong> can lead to <strong>unwanted hair growth</strong> in areas such as <strong>the face,</strong> which is evident in the<strong> image provided.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Methyldopa:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Methyldopa is an <strong>antihypertensive medication </strong>that can cause side effects such as <strong>drowsiness and dry mouth</strong> but is not commonly associated with hirsutism.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Captopril:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Captopril is an <strong>ACE inhibitor </strong>used to treat <strong>high blood pressure and heart failure</strong>. It can cause a persistent <strong>dry</strong> <strong>cough, taste changes, </strong>and in rare cases, <strong>angioedema,</strong> but not hirsutism.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Fenoldopam:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fenoldopam is a<strong> vasodilator </strong>used in <strong>hypertensive emergen</strong>cies, acting as a<strong> dopamine D1 receptor agonist</strong>. It does not have hirsutism listed as a side effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to recognize the<strong> important drugs</strong> causing <strong>hirsutism.&nbsp; </strong>These include:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Minoxidil</span></span></span></strong></li>\r\n\t<li style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclosporine</span></span></span></strong></li>\r\n\t<li style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenytoin</span></span></span></strong></li>\r\n\t<li style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgens</span></span></span></strong></li>\r\n</ul>",
    "correct_choice_id": 15080,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 3800,
    "choices": [
      {
        "id": 15179,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Na<sup>+</sup>- K<sup>+</sup>- ATPase inhibition</span></span></span></p>"
      },
      {
        "id": 15180,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha adrenergic blockade</span></span></span></p>"
      },
      {
        "id": 15181,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta adrenergic blockade</span></span></span></p>"
      },
      {
        "id": 15182,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Potassium channel opener</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antihypertensive drugs act by all the following mechanism except?</span></span></span></p>",
    "unique_key": "Q4737598",
    "question_audio": null,
    "question_video": null,
    "map_id": 36041,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Na<sup>+</sup>- K<sup>+</sup>- ATPase inhibition</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Na+- K+- ATPase inhibitor</strong>s, such as the <strong>digitalis group of drugs</strong>, are primarily used for the treatment of <strong>congestive heart failure (CHF)</strong> and not for hypertension. These drugs <strong>inhibit the Na+/K+ pump,</strong> which leads to an<strong> increase in intracellular sodium.</strong> This in turn affects the <strong>sodium-calcium exchange leading to an increase in intracellular calcium</strong> that improves <strong>cardiac contractility</strong> in patients with<strong> heart failure.</strong> However, they <strong>are not</strong> used to<strong> lower blood pressure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Alpha adrenergic blockade:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Alpha blockers</strong>, such as <strong>prazosin and terazosin, </strong>are indeed used in the treatment of <strong>hypertension</strong>. They work by <strong>blocking alpha-1 receptors,</strong> leading to <strong>vasodilation and decreased peripheral resistance.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Beta adrenergic blockade:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta blockers, such as <strong>metoprolol,</strong> are commonly used to manage<strong> hypertension.</strong> They reduce the<strong> heart rate and the force of the heart&#39;s contractions, lowering blood pressure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Potassium channel opener:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Potassium channel openers, like <strong>minoxidil and diazoxide</strong>, cause <strong>vasodilation</strong> by <strong>opening</strong> <strong>potassium channels in smooth muscle cells,</strong> which is also a mechanism that can be used in the<strong> treatment of hypertension.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> Na+- K+- ATPase inhibition </strong>mechanism is associated with<strong> digitalis drugs for CHF </strong>and<strong> not </strong>with the treatment of <strong>hypertension,</strong> whereas <strong>alpha and beta adrenergic blockade and potassium channel opening</strong> are valid mechanisms for <strong>antihypertensive drugs.</strong></span></span></span></p>",
    "correct_choice_id": 15179,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 3826,
    "choices": [
      {
        "id": 15283,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcium gluconate</span></span></span></p>"
      },
      {
        "id": 15284,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
      },
      {
        "id": 15285,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol</span></span></span></p>"
      },
      {
        "id": 15286,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tricyclic antidepressants</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drug precipitates digoxin toxicity by inhibiting the efflux proteins (P-glycoprotein) of digoxin? </span></span></span></p>",
    "unique_key": "Q8810329",
    "question_audio": null,
    "question_video": null,
    "map_id": 36037,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Quinidine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine is a<strong> Class IA antiarrhythmic </strong>medication that has been shown to <strong>inhibit P-glycoprotein (P-gp),</strong> the <strong>efflux transporter</strong> responsible for the <strong>elimination of digoxin from cells. Inhibition of P-gp by quinidine</strong> can lead to <strong>increased digoxin levels</strong> in the body, potentially precipitating <strong>digoxin toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Calcium gluconate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Calcium gluconate is<strong> not known</strong> to <strong>inhibit P-gp </strong>and <strong>does not</strong> precipitate <strong>digoxin toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Propranolol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Propranolol is a<strong> beta-blocker </strong>and d<strong>oes not inhibit P-gp.</strong> It may <strong>increase the risk of digoxin toxicity</strong> through additive <strong>negative chronotropic and dromotropic effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Tricyclic antidepressants:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Tricyclic antidepressants are <strong>not known to inhibit P-gp </strong>and <strong>do not </strong>directly precipitate<strong> digoxin</strong> <strong>toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to know the important <strong>drug interactions </strong>that can precipitate<strong> digoxin toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interactions of digoxin:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diuretics</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">:&nbsp;Cause<strong> hypokalemia</strong> which <strong>increases the risk of digitalis arrhythmias: potassium supplements</strong> should be given <strong>prophylactically.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcium</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Synergies with digitalis </strong>and thus <strong>precipitates toxicity.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Reduces its renal and biliary clearance</strong> by<strong> inhibiting efflux transporter P-glycoprotein</strong> leading to<strong> increase in</strong> <strong>plasma concentration of digoxin.</strong> <strong>Verapamil, clarithromycin and amiodarone </strong>also<strong> increase plasma concentration of digoxin to variable extents.</strong></span></span></span></li>\r\n</ol>",
    "correct_choice_id": 15284,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 23451,
    "choices": [
      {
        "id": 93768,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduce preload</span></span></span></p>"
      },
      {
        "id": 93769,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sildenafil may pronounce hypotension and should never be combined</span></span></span></p>"
      },
      {
        "id": 93770,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cause redistribution of coronary blood flow</span></span></span></p>"
      },
      {
        "id": 93771,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tolerance is most seen in sublingual administration of nitrates</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about the Nitrates in Angina are true except?</span></span></span></p>",
    "unique_key": "Q4394017",
    "question_audio": null,
    "question_video": null,
    "map_id": 36034,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Tolerance is most seen in sublingual administration of nitrates</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tolerance to nitrates </strong>develops when they are continuously present in the <strong>bloodstream for prolonged periods</strong>. This is more common with<strong> oral, transdermal, or continuous intravenous infusion of nitrates, </strong>as well as with <strong>long-acting agent</strong>s, particularly those in <strong>sustained release formulations.</strong> In contrast, there is <strong>no</strong> significant <strong>development of tolerance</strong> when <strong>sublingual nitrates </strong>are<strong> used</strong> <strong>intermittently for acute attacks of angina.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Reduce preload:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True</strong>. <strong>Nitrates predominantly dilate veins, </strong>leading to a <strong>reduction in preload,</strong> which <strong>decreases the amount</strong> of <strong>blood returning to the heart</strong>, thereby <strong>reducing the work the hear</strong>t has to <strong>do and the oxygen demand.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sildenafil may pronounce hypotension and should never be combined:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True.</strong> Combining<strong> nitrates with sildenafil </strong>can lead to dangerous potentiation of <strong>vasodilatory effects, </strong>resulting in <strong>severe hypotension,</strong> <strong>myocardial infarction, and even death.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Cause redistribution of coronary blood flow:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True</strong>. Nitrates preferentially <strong>dilate larger</strong> <strong>conducting coronary arteries </strong>over <strong>arterioles</strong>, which may facilitate<strong> increased blood flow to ischemic areas of the heart</strong> in patients with<strong> angina.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of angina treatment, <strong>nitrates </strong>are known to <strong>reduce preload </strong>and can cause <strong>redistribution of coronary blood flow</strong>, but <strong>significant tolerance</strong> is <strong>not</strong> typically associated<strong> with intermittent sublingual administration. </strong>It is also critical to <strong>avoid the</strong> <strong>combination of nitrates with sildenafil </strong>due to the <strong>risk of severe hypotension.</strong></span></span></span></p>",
    "correct_choice_id": 93771,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3859,
    "choices": [
      {
        "id": 15415,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrochlorothiazide </span></span></span></p>"
      },
      {
        "id": 15416,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atenolol</span></span></span></p>"
      },
      {
        "id": 15417,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prazosin </span></span></span></p>"
      },
      {
        "id": 15418,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enalapril</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following antihypertensive drug is avoided in patients with high serum uric acid levels? </span></span></span></p>",
    "unique_key": "Q6312218",
    "question_audio": null,
    "question_video": null,
    "map_id": 36039,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Hydrochlorothiazide</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hydrochlorothiazide</strong> is a <strong>thiazide diuretic</strong> commonly used as an <strong>antihypertensive agent.</strong> Thiazide diuretics can <strong>increase serum uric</strong> acid levels by<strong> reducing renal uric acid excretion,</strong> potentially leading to <strong>gout or exacerbating pre-existing hyperuricemia.</strong> Therefore, it is generally <strong>avoided or used with caution </strong>in patients with<strong> high serum uric acid levels </strong>or a<strong> history of gout.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Atenolol:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atenolol is a <strong>cardioselective beta-blocker </strong>that does not directly affect <strong>serum uric acid levels</strong>. It is <strong>not</strong> <strong>contraindicated in patients</strong> with<strong> high uric acid levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Prazosin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Prazosin is an <strong>alpha-1 adrenergic antagonist</strong> that <strong>does not</strong> affect serum <strong>uric acid levels</strong>. It is not contraindicated in patients with <strong>hyperuricemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong> <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enalapril</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Enalapril is an <strong>angiotensin-converting enzyme (ACE) inhibitor</strong> that<strong> does not </strong>significantly affect<strong> serum uric acid</strong> levels. It is generally considered safe for use in patients with<strong> high uric acid levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to understand the association between<strong> antihypertensive medications and serum uric acid levels</strong>. <strong>Thiazide diuretics</strong> like<strong> hydrochlorothiazide</strong> can<strong> increase serum uric acid levels </strong>and are typically <strong>avoided in patients</strong> with <strong>hyperuricemia or a history of gout. </strong></span></span></span></p>",
    "correct_choice_id": 15415,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3866,
    "choices": [
      {
        "id": 15443,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lisinopril</span></span></span></p>"
      },
      {
        "id": 15444,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clonidine</span></span></span></p>"
      },
      {
        "id": 15445,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nifedipine </span></span></span></p>"
      },
      {
        "id": 15446,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Timolol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient presented with the symptoms shown in the image below. Patient is a known hypertensive and was taking some antihypertensive drug. Which of the following drug is the likely cause of this condition? </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/51.jpg\" style=\"height:215px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q7722420",
    "question_audio": null,
    "question_video": null,
    "map_id": 36043,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Lisinopril </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given image is suggestive of <strong>angioedema </strong>which is a potential <strong>side effect of ACE inhibitors. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Clonidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clonidine, a <strong>centrally acting alpha-2 adrenergic agonist, </strong>is<strong> not</strong> typically associated with <strong>angioedema</strong>. Its main adverse effects include <strong>dry mouth, sedation, and rebound hypertension </strong>if <strong>discontinued abruptly.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Nifedipine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Nifedipine is a <strong>calcium channel blocker</strong> that <strong>primarily dilates arterial vessels</strong> and is commonly used to treat <strong>hypertension and angina</strong>. <strong>Angioedema is not </strong>a typical <strong>side effect</strong> of nifedipine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Timolol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Timolol is a <strong>non-selective beta-adrenergic blocker</strong> used to treat<strong> hypertension, angina, and glaucoma. </strong>While<strong> beta</strong> <strong>blockers </strong>can rarely cause<strong> angioedema</strong>, it is<strong> not</strong> a common <strong>side effect</strong> associated with <strong>timolol.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Angioedema</strong> is a<strong> rare</strong> but potentially <strong>serious adverse effect</strong> of <strong>ACE inhibitors</strong> like <strong>lisinopril.</strong> Recognizing this adverse reaction is essential for <strong>prompt discontinuation of the offending medication </strong>and <strong>initiation of appropriate management to prevent</strong> <strong>complications. </strong></span></span></span></p>",
    "correct_choice_id": 15443,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 23607,
    "choices": [
      {
        "id": 94393,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Levodopa</span></span></span></p>"
      },
      {
        "id": 94394,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbidopa</span></span></span></p>"
      },
      {
        "id": 94395,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha methyl dopa</span></span></span></p>"
      },
      {
        "id": 94396,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydralazine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following antihypertensive drug has a central sympatholytic action?</span></span></span></p>",
    "unique_key": "Q1466547",
    "question_audio": null,
    "question_video": null,
    "map_id": 36040,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Alpha methyl dopa&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Alpha-methyl dopa</strong> is an <strong>antihypertensive</strong> medication that acts<strong> centrally to reduce sympathetic outflow from the brainstem.</strong> It is a <strong>prodrug </strong>that is <strong>metabolized to alpha-methyl norepinephrine, </strong>which acts as a <strong>false neurotransmitter</strong> in the central nervous system. By <strong>acting on central alpha-2 adrenergic receptors,</strong> <strong>alpha-methyl dopa reduces sympathetic tone,</strong> leading to <strong>vasodilation and</strong> <strong>decreased blood pressure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Levodopa</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Levodopa is <strong>not</strong> an <strong>antihypertensive drug;</strong> it is primarily used in the treatment of<strong> Parkinson&#39;s disease to</strong> <strong>replenish dopamine levels</strong> in the brain.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Carbidopa</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Carbidopa is often <strong>co-administered with levodopa </strong>to<strong> enhance its therapeutic effects</strong> in <strong>Parkinson&#39;s disease</strong>. It <strong>does not</strong> have <strong>antihypertensive properties.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hydralazine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Hydralazine is a<strong> direct-acting vasodilator </strong>that primarily<strong> acts on arterial smooth muscle to decrease peripheral</strong> <strong>resistance and lower blood pressure.</strong> It<strong> does not</strong> exert its effects through <strong>central sympatholytic mechanisms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the <strong>mechanisms of action of different antihypertensive drugs</strong> is important for<strong> selecting appropriate medications</strong> based on the <strong>patient&#39;s condition and comorbidities</strong>. <strong>Alpha-methyl dopa</strong> is a <strong>centrally acting antihypertensive agent</strong> that<strong> reduces</strong> <strong>sympathetic outflow </strong>from the<strong> brainstem, leading to vasodilation and decreased blood pressure.</strong></span></span></span></p>",
    "correct_choice_id": 94395,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 3828,
    "choices": [
      {
        "id": 15291,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydralazine</span></span></span></p>"
      },
      {
        "id": 15292,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diazoxide</span></span></span></p>"
      },
      {
        "id": 15293,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Minoxidil</span></span></span></p>"
      },
      {
        "id": 15294,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nicorandil</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The side-effect of which of the following drug is used as a therapeutic advantage in alopecia?</span></span></p>",
    "unique_key": "Q6114469",
    "question_audio": null,
    "question_video": null,
    "map_id": 36033,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Minoxidil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Minoxidil </strong>is a medication primarily used to<strong> treat hair loss (alopecia) in both men and women</strong>. Its side effect of <strong>promoting hair</strong> <strong>growth</strong> was discovered incidentally during its <strong>initial use as an oral medication</strong> to treat<strong> high blood pressure</strong>. The topical formulation of <strong>minoxidil</strong> is now <strong>widely used</strong> as a treatment for <strong>androgenetic alopecia (male-pattern baldness and female-pattern hair loss).</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hydralazine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hydralazine is an <strong>antihypertensive</strong> medication that<strong> does not</strong> have a therapeutic advantage in <strong>alopecia.</strong> It <strong>does not promote hair growth </strong>and is <strong>not </strong>used in the treatment of<strong> alopecia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Diazoxide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Diazoxide is a medication used to<strong> treat hypoglycemia and hypertensive emergencies</strong>. It is<strong> not </strong>associated with any therapeutic advantage in<strong> alopecia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Nicorandil:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Nicorandil is a<strong> vasodilator medication </strong>used to treat<strong> angina pectoris.</strong> It <strong>does not </strong>have a therapeutic advantage in <strong>alopecia </strong>and is <strong>not</strong> used for this purpose.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the<strong> therapeutic use of minoxidil</strong> in the treatment of<strong> alopecia </strong>and how its<strong> side effect of</strong> <strong>promoting hair growth</strong> is <strong>exploited for this purpose</strong>. Recognizing medications with <strong>beneficial side effects allows clinicians to repurpose drugs for new indications and optimize patient care.</strong></span></span></span></p>",
    "correct_choice_id": 15293,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 3586,
    "choices": [
      {
        "id": 14323,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clarithromycin</span></span></span></p>"
      },
      {
        "id": 14324,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxycodone</span></span></span></p>"
      },
      {
        "id": 14325,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rivaroxaban </span></span></span></p>"
      },
      {
        "id": 14326,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adalimumab</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient is taking atorvastatin for dyslipidemia. Which of these drugs should be avoided in this patient?<strong> </strong></span></span></span></p>",
    "unique_key": "Q8659814",
    "question_audio": null,
    "question_video": null,
    "map_id": 36031,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Clarithromycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Clarithromycin </strong>should be <strong>avoided</strong> in patients taking <strong>atorvastatin for dyslipidemia</strong>. Atorvastatin, like other <strong>statins,</strong> is <strong>metabolized</strong> by the <strong>cytochrome P450 3A4 (CYP3A4) enzyme system</strong>. Clarithromycin is a known <strong>inhibitor of the CYP3A4 enzyme,</strong> which can lead to <strong>increased plasma levels of atorvastatin.</strong> When its <strong>plasma levels rise </strong>significantly, there is an<strong> increased risk of serious adverse effects</strong> such as <strong>myopathy</strong>, which includes<strong> muscle pain, tenderness, or weakness</strong> with elevated levels of<strong> creatine kinase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Oxycodone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because oxycodone, an<strong> opioid analgesic,</strong> <strong>does not</strong> significantly interact with the<strong> CYP3A4 enzyme</strong> in a way that would affect the <strong>metabolism of atorvastatin to a clinically relevant extent.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Rivaroxaban:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as <strong>rivaroxaban,</strong> an <strong>anticoagulant</strong>, is<strong> not metabolized by CYP3A4</strong> in a way that would interfere with <strong>atorvastatin metabolism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Adalimumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> because <strong>adalimumab</strong>, an <strong>immunosuppressive drug</strong> used to treat <strong>autoimmune diseases, does not</strong> interact with the<strong> CYP3A4 enzyme </strong>and thus<strong> would not </strong>affect <strong>atorvastatin levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When prescribing <strong>statins,</strong> <strong>avoid </strong>concomitant use with drugs that<strong> inhibit CYP3A4,</strong> such as <strong>clarithromycin,</strong> to prevent an<strong> increase</strong> in their <strong>plasma levels</strong> which could <strong>lead to myopathy. </strong>Other notable<strong> CYP3A4 inhibitors</strong> to avoid include <strong>amiodarone, gemfibrozil, HIV</strong> <strong>protease inhibitors (such as saquinavir, ritonavir), and itraconazole.</strong></span></span></span></p>",
    "correct_choice_id": 14323,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 3747,
    "choices": [
      {
        "id": 14967,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old woman with type 1 diabetes with two positive spot microalbuminuria tests 1 week apart</span></span></span></p>"
      },
      {
        "id": 14968,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman with type 1 diabetes with a blood glucose of 328 mg/dL and a positive spot microalbuminuria test</span></span></span></p>"
      },
      {
        "id": 14969,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old man with type 2 diabetes with a positive spot microalbuminuria test 1 week after starting a new exercise program</span></span></span></p>"
      },
      {
        "id": 14970,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart&nbsp;</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following patients should be treated with either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker?</span></span></span></p>",
    "unique_key": "Q6591996",
    "question_audio": null,
    "question_video": null,
    "map_id": 36032,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> use of ACE inhibitors or ARBs</strong> is indicated in patients with diabetes who exhibit <strong>persistent microalbuminuria, </strong>as this is a marker of <strong>early diabetic nephropathy. </strong>It is<strong> essential to confirm persistent microalbuminuria </strong>with at<strong> least two positive tests</strong> <strong>spaced 3 to 6</strong> months apart, in the absence of other conditions that might<strong> cause transient increases in albumin excretion.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The testing <strong>interval of 1 week</strong> is too soon for confirmation of <strong>persistent microalbuminuria. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The presence of<strong> severe hyperglycemia </strong>can <strong>transiently increase albumin excretion</strong>, potentially confounding the <strong>test result. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Vigorous exercise </strong>can also transiently <strong>increase albumin excretion,</strong> making the test result unreliable.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the management of<strong> diabetic nephropathy, ACE inhibitors or ARBs </strong>should be initiated in patients with <strong>type 2 diabetes</strong> who have <strong>confirmed persistent microalbuminuria, </strong>indicated by <strong>at least two positive microalbuminuria tests </strong>spaced<strong> 3 to 6 months </strong>apart, <strong>without </strong>the influence of <strong>confounding factors.</strong></span></span></span></p>",
    "correct_choice_id": 14970,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  }
];
        let quizName = 'Cardiovascular System';
        let hierarchy = ["Cerebellum", "qBank", "Pharmacology"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }
            
            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>